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This study investigated the in vitro antithrombotic properties of the lipids extracted from 
malted grain (MG), brewer’s spent grain (BSG), raw hops (RWHP), spent hops (SPHP), 
wort, and beer. Total lipids (TL) were extracted according to the Bligh & Dyer method and 
further separated into total polar lipid (TPL) and total neutral lipid (TNL) using a modified 
counter-current distribution method. The TPL of the beer was further fractionated by TLC 
and isolated bands were extracted.  The antithrombotic activities of the TL, TPL and TNL 
of the MG, BSG, RWHP and SPHP were analysed in vitro for their ability to inhibit platelet-
activating factor (PAF) induced aggregation in human platelets. Seven bands extracted by 
preparative TLC of the beer TPL were also tested for the ability to inhibit PAF induced 
platelet aggregation. This study demonstrated that the TPL extracts were the most bioactive 
with the exception of BSG as the TL displayed potent antithrombotic activity. The wort and 
beer TPL displayed the most potent inhibitory activity against PAF induced platelet 
aggregation. However, the beer TPL possessed the strongest inhibitory activity against PAF 
with the lowest IC50 value (7.8 ± 3.9 µg) and it was noted that fermentation of the wort 
increased the antithrombotic activity, which may warrant further investigation. The TLC 
bands 2 and 3 of the beer TPL exhibited potent inhibitory activity against PAF, which may 
be due to the presence of phenolic compounds. The fatty acid composition of the TPL 
extracts of all samples were analysed by gas chromatography-mass spectrometry (GC-MS). 
The GC-MS analysis of the TPL found that the wort and beer shared similar fatty acid 
compositions. The findings of this study provide new information into the effect of 
fermentation on the fatty acid composition and antithrombotic properties of beer. Further 
structural and functional studies are required to identify the exact compounds responsible 
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1.1 Cardiovascular Disease  
Cardiovascular disease (CVD) is a term used to describe a set of diseases that affect the heart 
and/or circulatory system. CVD is the number one cause of death worldwide, causing the 
deaths of 17.9 million people, of which 85% were attributed to heart attack and stroke 
(World Health Organisation 2017). In Europe, this number stands at 3.9 million people killed 
by CVD related diseases. In Ireland alone, it is estimated that 10,000 people die each year 
due to CVD (Irish Heart Foundation 2019). CVD is the leading cause of death in men in all 
but twelve countries and for women it is the leading cause of death in all but two countries 
in Europe (Wilkins et al. 2017). Due to the severity of this problem, research into the 
prevention of atherosclerosis and other precursors of CVD are a major objective of modern 
medical investigation. 
 The term cardiovascular disease covers a spectrum of heart complications such as 
coronary heart disease (CHD), ischaemic heart disease, stroke, peripheral artery disease, 
rheumatic heart disease, congenital heart disease, and heart failure. There is a broad range 
of CVD related illnesses that all relate to one another and the heart and circulatory system. 
There are numerous known risk factors for CVD, many of which are preventable. Despite 
this, CVD is still the number one cause of death globally (World Health Organisation 2017). 
While it is known that some risk factors for CVD cannot be prevented by an individual, such 
as a family history of heart disease or type I diabetes mellitus, many are known and 
avoidable. Many of these CVD risk factors include an unhealthy diet, lack of or insufficient 
exercise, smoking, and excessive consumption of alcohol.   
1.2 Human and Economic Impact of Cardiovascular Disease  
Developing countries have the highest rate of mortality with an estimated 82% of the 
total premature deaths caused by noncommunicable diseases and 37% of these deaths are 
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caused by CVDs. This is a trend that the World Health Organisation predicts will continue 
to rise. This will continue putting major pressure on health services around the world, as 
well as increasing financial pressure on individuals paying for treatment of CVD, many of 
whom struggle to afford it (World Health Organisation 2017).  
 In Ireland, CVD places a substantial economic strain on the Health Service Executive 
(HSE). A 2015 report into the cost of heart failure not only demonstrated the economic cost 
of heart failure to the individual/patient, the healthcare system, and society in Ireland, but it 
also demonstrated that these trends will continue to worsen unless preventative strategies 
and effective therapies are developed. The estimated cost of heart failure in Ireland amounts 
to approximately €660 million per year. These costs relate to the treatment of the initial 
event and hospitalisation, the after care of the patient, general practitioner appointments, 
clinical specialist appointments, and ambulance services (Irish Heart Foundation 2015).   
 
1.3 Causes of Cardiovascular Disease 
The chances of a person developing CVD can vary dramatically from one individual 
to the next depending on one’s exposure to certain modifiable and unmodifiable risk factors. 
Having one or more of these risk factors does not indicate the development of CVD but it 
does give an indication as to the risk of developing these diseases (World Heart Federation 
2017). Risk factors that are due to an individual’s decision or lifestyle that can be changed 
to reduce their risk of developing the condition are classified as modifiable risks.  These are 
characterised by a conscious decision(s) that an individual knows will lead to either a 
reduction of increased risk of developing CVD, these are discussed further in section 1.3.1 




1.3.1 Unmodifiable Risk Factors 
Unmodifiable risk factors increase the chances of developing CVD based on some 
factors that are out of the control of the individual. Family history of heart disease, age, and 
ethnic background are three common non-modifiable risks. 
The incidence of a cardiovascular event i.e. stroke, myocardial infarction, in a first-
degree male relative such as a brother or father can dramatically increase that individual’s 
chances of suffering from a cardiovascular event. The presence of heart disease amongst 
both parents can increase that person’s chances of developing a CVD to over 50% in 
comparison to the general population (World Heart Federation 2017). One directly 
inheritable risk factor is familial hypercholesterolemia (FH) which is an inherited condition 
characterised by levels of low-density lipoprotein cholesterol (LDLc) that far exceed normal 
physiological levels, putting them at an increased risk for premature CVD (Sharifi et al. 
2016). Premature CVD in men refers to a cardiovascular event <51 years and <56 years in 
women (Mulders et al. 2011). 
Ageing is a natural and inevitable part of life and as we get older our risk of 
developing CVD or associated diseases increases. The average lifespan continues to rise and 
it is expected that by the year 2030 almost 20% of the world’s population will be aged 65 
and older, and within this age group, CVD is expected to be the main cause of death (North 
and Sinclair 2012). With an increase in population in the over 65 age bracket by 2030 and 
the associated increased risk of CVD, it is expected that the cost of treatment of CVD will 
also rise meaning that more awareness and preventative measures are required (Heidenreich 




1.3.2 Modifiable Risk Factors  
Modifiable risk factors refer to the modifiable components in an individual’s lifestyle 
that can impact their risk of developing CVD such as diet, behaviour, and lifestyle. In the 
battle against CVD, prevention is key and unlike the unmodifiable risk factors, measures 
can be taken to alter the lifestyle of an individual to lower the risk of CVD. Increasing 
physical activity, eliminating unhealthy behavioural patterns like smoking, and following a 
healthy dietary pattern as outlined below are examples of positive measures that can be taken 
to lower CVD risk.  
Exercise is a pivotal modifiable risk factor for the prevention of many chronic diseases 
and physical inactivity can raise the incidence of up to 17 diseases, most of which are chronic 
diseases, including CVD (Booth et al. 2000).  This demonstrates the importance of exercise 
as a point of primary prevention of numerous diseases. However, an investigation into the 
dietary and lifestyle habits of the Irish population, the SLÁN study, found that only 41% of 
Irish adults took part in moderate or strenuous physical activity for at least 20 minutes three 
or more times a week (Morgan et al. 2008). These statistics highlight the burden the Irish 
population put on themselves as it has been reported that even performing higher levels of 
moderate physical activity can reduce CHD related events by 21% in men and 29% in 
women (Li and Siegrist 2012).  
Another prominent modifiable risk factor of CVD is smoking. It has long been known 
that smoking has been linked to many chronic diseases. The reason being that cigarette 
(tobacco) smoke affects smokers via multiple complex metabolic pathways involving 
exposure to free radicals from the components of tobacco smoke, leading to increased 
oxidative stress, inflammation, and DNA damage which can link smoking to many chronic 
diseases (Onor et al. 2017). Continued use of tobacco can dramatically reduce the overall 
health and wellbeing of an individual but eliminating tobacco use can improve an 
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individual’s health by reducing their risk of a myocardial infarction by 65% dependent on 
other factors related the individual (Yusuf et al. 2004). 
Along with the other modifiable risk factors, diet plays a critical role in CVD prevention. 
There is an ever-growing collection of data that supports the evidence demonstrating the 
pivotal role of nutrition in the development of numerous chronic diseases such as CVD. Diet 
and lifestyle are a key modifiable risk factors in the battle against CVD as can be seen when 
contrasting the dietary differences in parts of the world with the prevalence of CVD (Keys 
et al. 1984). Various dietary and environmental factors come into play when assessing CVD 
risk, however there is evidence to suggest that an individual’s diet plays a significant role in 
determining their risk of developing CVD. In particular, comparison of individuals that 
abide by the DASH and Mediterranean diets compared to those that follow an unhealthy 
Westernised diet, indicates that diet can reduce one’s risk of developing CVD. The DASH 
diet is a dietary pattern that targets the reduction of blood pressure, as high blood pressure 
increases one’s risk of developing CHD, stroke, and cardiovascular events (Tyson et al. 
2012). The original DASH diet was based on a low fat, less than 30% of total calories, and 
higher carbohydrate, ~55%, but has since reduced the percentage of energy for 
carbohydrates in exchange for additional vegetables and protein sources (Mozaffarian et al. 
2011). The diet is characterised by low-fat dairy foods and reduced saturated fat intake that 
was found to significantly reduce blood pressure (Appel et al. 1997) and with lower rates of 
heart failure (Levitan et al. 2009). While the DASH diet has demonstrated relative success, 
the diet with the most evidence to support its role in preventing CVD is the Mediterranean 
diet (Tsoupras et al. 2018b). The Mediterranean diet consists of a high dietary intake of 
fruits, vegetables, wholegrain/wheat based cereal products, and monounsaturated fats. This 
is paired with fish, dairy, and alcohol consumption in moderation and a low intake of red 
and processed meats with more emphasis being placed on fish intake than other meats 
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(Tsoupras et al. 2018b). This diet has been the subject of numerous studies and has 
consistently shown a significant and consistent protection when the Mediterranean diet is 
adhered to against CVD and other chronic diseases (Sofi et al. 2010; Estruch et al. 2018).  
 
1.4 Inflammation and Atherosclerosis 
Inflammation is our body’s natural defence mechanism and is a very complex 
response that is designed to protect us in the event of traumatic injury or against infectious 
organisms. It is a physiological process that is vital for the repair of tissue and the elimination 
of pathogenic insults (Tsoupras et al. 2018b). Inflammation is generally divided into acute 
inflammation, which is a response to tissue injury or a physical stressor, and 
chronic/systemic inflammation, the prolonged tissue reaction following the initial reaction 
that is often dominated by lymphocytes, plasma cells and macrophages. CVD is 
characterised by chronic inflammation as it takes place over a long period of time and the 
progression of CVD is influenced by its associated risk factors. This chronic inflammation 
is not only linked to CVD, but it is also an underlying feature of a variety of other chronic 
diseases, such certain cancers and type 2 diabetes, further emphasising the fact that 
understanding the development of systemic inflammation is key to the primary prevention 
of such diseases (Stokes and Granger 2012).  
 This inflammatory response aims to restore tissue homeostasis. This response is 
initiated by innate sensing mechanisms that detect the stressor such as infection by 
pathogens, stressed or dying cells releasing chemokines or a barrier breach in the endothelial 
cells of blood vessels. A cascade of inflammatory and mechanistic effects is well-
orchestrated by the immune system in order to eradicate the causative agent (Tsoupras et al. 
2018b). The immune system swiftly responds to any of these stressors with several immune 
cells being sent to/synthesized at the site of damage in an effort to remove the agent causing 
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the inflammatory response (Spinas et al. 2014). Should the removal of the stressor by the 
acute inflammatory response be successful the inflammatory response is terminated, and 
normal tissue function can resume. However, if the inflammatory response was unable to 
adequately repair the tissue injury, the inflammatory response becomes unresolved and 
systemic inflammation occurs leading to further tissue dysfunction (Tsoupras et al. 2018b). 
This can be associated with the development of an atherosclerotic plaque. Animal models 
have demonstrated systemic inflammation where lipid accumulation in the artery wall has 
occurred due to the presence of localised inflammatory markers such as blood leukocytes 
and platelet- activating factor (PAF), which are present in the early lesions of atherosclerotic 
plaque. This demonstrates the role inflammation plays in the onset and development of 
atherosclerosis (Li et al. 1993; Libby 2012).  
Atherosclerosis is a chronic inflammatory disease resulting in the development of a 
plaque on the walls of medium and large arteries, occurring due to the failure of the 
inflammatory response system to remove the causative agent of the inflammation or repair 
the injured tissue. Atherosclerosis is characterised by the formation of plaques consisting of 
a necrotic core, calcified regions, accumulated modified lipids, inflamed smooth muscle 
cells, endothelial cells, leukocytes and foam cells (Ross and Dodet 1999). The presence of 
any of the risk factors associated with CVD can be attributed to the development of one of 
these atherosclerotic plaques. For example, toxins introduced into the bloodstream by 
smoking can cause damage to parts of the endothelial layer. Circulating in the blood, LDLc 
begins to bind to proteoglycans and migrate into the tunica intima at the site of damaged 
endothelial layer. The affinity of LDLc for the artery wall can be described by the attraction 
of positively charged amino acids from apolipoprotein B100 of LDLc interacting with the 
negatively charged sulphate or carboxylic acid groups from glycosaminoglycans (Flood et 
al. 2004). This affinity for the arterial wall allows LDLc to move into the intima in areas 
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where there is damage to the endothelial wall. Once inside the intima, the LDLc begins to 
oxidise, triggering an immune response as oxidised LDLc is toxic to endothelial cells. This 
lipid oxidation can cause the expression of adhesion molecules by damaged endothelial cells 
and the recruitment of chemokines, proinflammatory cytokines, and other mediators of 
inflammation to the affected region. These selective adhesion molecules allow for the 
recruitment of certain leukocytes such as macrophages in the earlier stages of atherosclerosis 
(Libby 2012). This endothelial activation and dysfunction results in the upregulating of 
adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), P-selectin as well 
as monocyte chemotactic proteins such as CCL2 that facilitate the recruitment of monocytes 
(Angelovich et al. 2015).  
Monocytes react to these adhesion molecules such as P-selectin, initiating the rolling of 
the monocyte along the endothelium until it comes into contact with VCAM-1, where rolling 
slows and the monocyte tightens to the endothelium (Galkina and Ley 2007). These 
monocytes migrate into the atherosclerotic prone region where they differentiate into 
macrophages for LDLc removal (Galkina and Ley 2009). The expression of scavenger 
proteins on the surface of these macrophages allows them to ingest lipids, as more LDLc 
migrates to the intima. These macrophages eventually reach capacity and differentiate into 
foam cells and as these started as monocytes, the death of these cells triggers the release of 
cytokines (Libby 2012). The production and release of proinflammatory cytokines and 
chemokines such as tumour necrosis factor and macrophage inflammatory protein-1 drives 
the inflammation further as the atherosclerotic plaque grows (Wong et al. 2012). As the 
inflammatory response intensifies, activated leukocytes and other intrinsic arterial cells 
release fibrogenic mediators such as cytokines that promote the replication of smooth muscle 
cells of the tunica media and their migration into the atherosclerotic plaque (Galkina and 
Ley 2009). These cells are responsible for the formation of connective tissue, and in 
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atherosclerotic lesions these tissues are fibrous and form around the plaque that overlies the 
necrotic core shielding it from the bloodstream (Ross and Dodet 1999). However, the death 
of these smooth muscle cells over time further hinders the arteries, as apoptosis of smooth 
muscle cells promotes the calcification of the matrix causing stiffening of the arteries 
(Durham et al. 2018). Eventual degradation of the fibrous cap by mechanical stress from the 
blood-flow through the occluding artery or enzymes secreted by macrophages that are 
capable of breaking down the extracellular matrix can reduce the cap strength (Arroyo and 
Lee 1999). Weakening of the fibrous cap can leave it prone to rupture. Upon rupture, it can 
expose the thrombogenic lipid core, red-cell rich necrotic core material within the cap to the 
bloodstream resulting in coagulation and thrombosis within the affected artery, potentially 
causing complete occlusion of the artery resulting in a cardiovascular event such as 
myocardial infarction or ischemic stroke (Bentzon et al. 2014).  
 
1.5 The Role of Platelet-Activating Factor 
 Platelet-activating factor (PAF) is a potent proinflammatory mediator, the function 
of which under normal and inflammatory conditions has been the subject of research for 
many years. The term PAF was originally used in 1972 by Benveniste et al in his research, 
revealing that it is released from rabbit basophils in an Immunoglobulin E-dependent process 
(Benveniste et al. 1972). Not much was known of PAF structure or function at this point 
until two independent studies were able to describe the structure of PAF as 1-O-alkyl-2-
acetyl-sn-glycero-phosphocholine, with the classic model being an alkyl ether linkage at 
position sn-1, acetyl group at position sn-2 and a phosphocholine group at position sn-3 as 
seen in Figure 1.1 (Benveniste et al. 1979; Demopoulos et al. 1979). Since its discovery, it 
has been associated with a number of roles within the body under normal conditions but also 
as a vital mediator during inflammatory conditions within the body, being synthesised by 
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several cells upon activation such as platelets, monocytes, macrophages, foam cells as well 
as endothelial cells, further highlighting the role it plays in atherosclerosis (Demopoulos et 




Figure 1.1. (A) Typical structure of a PAF molecule. (B) Image representing a biologically 
active phospholipid that mimics PAF.  
Reproduced with permission from (Lordan et al. 2018a).  
 
The synthesis of PAF within the body is tightly regulated due to its potency and role 
in a diverse range of functions. Two distinct pathways are known to exist depending on the 
requirements of the body. The first of these pathways, the ‘de novo’ pathway, is responsible 
for the basal levels of PAF. PAF synthesised by this route, often in the brain and kidneys, 
serves a role primarily in homeostasis, maintaining the PAF levels throughout the body for 
normal cellular functions (Palur Ramakrishnan et al. 2017). PAF is synthesised from the 
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substrates alkylacetylglycerol and Cytidine diphosphate (CDP)-choline. The initial step of 
the ‘de novo’ pathway is the acetylation of alkylglycerol-P by the catalytic action of the 
enzyme acetyltransferase to form alkylacetylglycerol-P before dephosphorylation by a 
specific phosphohydrolase reduces alkylacetylglycerol-P to alkylacetylglycerol, one of the 
two primary substrates in the formation of PAF. The final step is catalysed by diacylglycerol 
cholinephosphotransferase (EC 2.7.8.16) that utilises the aforementioned 
alkylacetylglycerol and CDP-choline as co-substrates to form PAF via the ‘de novo’ 
pathway (Snyder 1997).  
 The alternative pathway by which PAF is produced is the remodelling pathway, that 
tends to be associated more with the acute proinflammatory production of PAF under 
activation of several cells during inflammatory conditions (Tsoupras et al. 2018b). By this 
pathway, PAF is synthesised by many cells in response to specific stimuli including 
cytokines, endotoxins, Ca2+ ionophores, and also in response to PAF itself, highlighting why 
it is be believed that PAF is a common mediator among many chronic inflammatory diseases 
(Lordan et al. 2019b). During inflammatory conditions, the ether analogue of 
phosphatidylcholine (PC) is converted to lyso-PAF by the action of phospholipase A2. This 
lyso-PAF, an inactive form of PAF, is then acetylated by isoforms of acetyl-CoA and lyso-
PAF transferases to yield the biologically active form of PAF (Lordan et al. 2019b).   
 PAF is synthesised by several cells (e.g. macrophages, foam cells, endothelial cells, 
and platelets) involved in the inflammatory process of atherosclerosis once they are 
activated. PAF and PAF-like lipids act through their high affinity binding to a unique G-
protein coupled seven transmembrane receptors called a PAF-receptor (PAF-R), expressed 
on the surface of various cells (Honda et al. 2002). PAF or PAF like molecules upon binding 
to the PAF-R activates multiple intracellular pathways in blood or tissue cells bearing the 
PAF-R and can cause a cascade of intracellular responses that in many cases initiate or 
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amplify inflammatory processes (Yost et al. 2010). The role of PAF in the inflammatory 
process of atherosclerosis has been reported in studies from initiation and recruitment of 
inflammatory cells to and across the endothelium by promoting the surface expression of 
adhesion molecules, right up to the rupture of the fibrous cap at which point platelets 
activated during binding to the ruptured endothelium release PAF and subsequent 
overexpression of PAF to the site of rupture, resulting in continuous recruitment, 
aggregation and subsequent thrombosis (Zimmerman et al. 2002; Palur Ramakrishnan et al. 
2017). 
 Without specific binding to the PAF-R, PAF synthesis and activation capabilities are 
lowered, demonstrating that potential therapeutic approaches to these inflammatory actions 
should focus on the PAF-R and its interactions, inhibiting the exacerbation of the PAF-
induced response model through competitive and non-competitive displacement of PAF 
from the PAF-R by PAF-R antagonists (Lordan et al. 2018b). PAF-R antagonists that act in 
this way are often polar lipid extracts from foods associated with that of the Mediterranean 
diet such as olive oil, wine, dairy, and fish, all of which have shown promising results due 
to the polar lipids ability to act on the PAF-R (Karantonis et al. 2006; Tsantila et al. 2007; 




Figure 1.2. An image demonstrating the role of PAF and PAF-R in response to 
inflammatory stimuli.  
(A1) Pro-inflammatory stimuli stimulate the syntheses of PAF and the expression of PAF-
R on the surface of cells which can result in the amplification of certain pro-inflammatory 
stimuli. (A2) The binding of PAF to PAF-R signals the initiation of several inflammatory 
responses such as the release of PAF from the activated cells and the production of more 
arachidonic acid within the body to be used as a substrate in the formation of more PAF. 
(A3) Further activation of PAF-R on the surface of cells signals the release of chemokines, 
expression of adhesion molecules on endothelial cells, and release/synthesis of PAF, further 
amplifying the inflammatory response. This results in the cellular signalling for the 
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recruitment of lymphocytes to the site of inflammation where lymphatic cells bind to the 
adhesion molecules expressed on the surface of the damaged endothelial cells. (B)  The 
inflammatory cascade leads to an increase in the concentration of PAF at the site of 
inflammation and so promotes a broad spectrum of effects caused by the increased levels of 
PAF and other pro-inflammatory mediators circulating the blood. The increased levels of 
PAF, chemokines, and other inflammatory mediators in the bloodstream causes further 
activation of PAF-R. This promotes the aggregation of platelets and leukocytes and 
subsequent damage and activation of other endothelial cells downstream. These damaged 
endothelial cells promote leukocyte adherence, invasion, migration and subsequent 
endothelial dysfunction, thus stimulating the development of an inflammatory-related 
chronic disorders as seen in this image.  (C) Demonstrates how PAF antagonists, such as 
microconstituents of the Mediterranean diet, can act to disrupt the binding of PAF to the 
PAF-R. This disruption of PAF, possibly occurs by competitive displacement and, could aid 
in lowering PAF concentrations in the blood (Image reproduced with permission from 
Tsoupras 2018b). 
Abbreviations: AA = arachidonic acid; AC = adenylate cyclase; ACS = acute coronary 
syndrome; Akt = protein kinase B; ATP = adenosine triphosphoric acid; cAMP = cyclic 
adenosine monophosphate; CNS = central nervous system.; COX: cyclooxygenase; cPLA2 
= cytosolic phospholipase A2; CVD = cardiovascular diseases;  DAG = diacylglycerol; 
eNOS = endothelial nitric oxide synthase; ERK = extracellular signal-regulated kinases; IL 
= interleukin; iNOS = nitric oxide synthase; LPCAT = acetyl-CoA: lyso-PAF 
acetyltransferases ; MAPK = mitogen activated protein kinase; MMP = metalloproteinase; 
mTOR = mechanistic target of rapamycin; NADPO = nicotinamide-adenine dinucleotide 
phosphate oxidase; NF-kB = nuclear factor-kappa light-chain-enhancer of activated B cells; 
TNF-α = tumour necrosis factor; PAF = platelet activating factor; PAF-R = Platelet-
activating factor receptor; PI3K: phosphatidylinositol 3-kinase; PKC = protein kinase C; 
PKA = protein kinase A; PLC = phospholipase C; RNS = reactive nitrogen species; ROS = 
reactive oxygen species; VEGF = vascular endothelial growth factor; XO = xanthine 
oxidase; 
 
1.6 Polar Lipids  
Lipids are a heterogenic class of biomolecules with wide ranging structures and 
functions. The two major sub-classes of lipids are neutral lipids and polar lipids. Neutral 
lipids, such as triacylglycerols, waxes, and terpenes, consist of hydrophobic, hydrocarbon 
chains bound to a glycerol backbone. The primary difference between neutral lipids and 
polar lipids is the absence of a charged phosphate group in the neutral lipids. Polar lipids, 
such as phospholipids and glycolipids, also contain the hydrophobic hydrocarbon tails 
bound to a glycerol, accompanied by a carbohydrate-group or phosphate-head group with a 
hydrophilic residue within their structure (Lordan et al. 2017). These phospholipids can be 
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found in all plant and animal cell membranes. Their amphipathic properties allow them to 
form a lipid bilayer, most of these cell membranes being made up of glycerophospholipids 
(Küllenberg et al. 2012). These glycerophospholipids share the common structure of two 
fatty acid molecules esterified to the glycerol backbone in the sn-1 and sn-2 positions of the 
molecule contributing to the hydrophobicity of the molecule while a phosphate group at the 
sn-3 position gives the molecule its hydrophilicity. This is known as phosphatic acid and is 
the simplest glycerophospholipid, with others being named in accordance with the molecule 
that attaches to the phosphate group. The main groups are ethanolamine, inositol, serine and 
choline that yield phosphatidylethanolamine (PE), phosphatidylinositol (PI), 
phosphatidylserine (PS) and (PC) respectively (Castro-Gómez et al. 2015) 
.  
 
Figure 1.3 (A) Structural representation of a triglyceride molecule. (B) Structural 
representation of a polar lipid molecule.  
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The polar lipid structure bears two hydrophobic, hydrocarbon chains esterified to the 
glycerol backbone in the sn-1 and sn-2 position, with a charged phosphate group at the sn-3 
position. (C) The headgroup that attaches to the phosphate molecule and gives the molecule 
its hydrophilic properties (Imaged reproduced with permission from Burri et al 2012) 
 
 The integrity of the phospholipid bilayer is essential to mammalian life; no 
membranes or cells are formed without these. The bilayer is formed in accordance with the 
amphiphilic nature of the lipid with hydrophobic hydrocarbon tail orientated to the interior 
of the cell membrane, while the hydrophilic polar group orientate toward the outer surface 
of the cell membrane in order to interact with the water phase providing a low-permeability 
to certain cellular constituents such as nutrients or ions while the formation of this lipid 





Figure 1.4. Image representation of the phospholipid bilayer.  
The Image displays how polar lipids are orientated in a phospholipid bilayer, with the polar 
hydrophilic head having a greater affinity for the aqueous phase. The hydrocarbon tails are 
highly hydrophobic, so lipid molecules orientate as displayed in this image to avoid 
interaction with the aqueous phase. This bilayer is essential for mammalian life as the 
formation of membranes or cells cannot be formed without it. (Image reproduced with 




 These polar lipids not only play a role in cellular functions but dietary polar lipids 
from various food sources have displayed anti-inflammatory properties against PAF. These 
anti-inflammatory properties have been attributed to polar lipids ability to interrupt the 
action of PAF on PAF-R through competitive and non-competitive displacement of PAF 
from the PAF-R, and through the modulation of PAF metabolic enzymes toward 
homeopathic PAF levels (Nasopoulou et al. 2011; Lordan et al. 2019c). The anti-PAF 
potential of lipids from various dietary sources has been investigated, with evidence 
suggesting that the most potent anti-inflammatory polar lipids were found in foods 
associated with the Mediterranean diet such as fish, olive oil, wine, and dairy products 
(Fragopoulou et al. 2001; Tsantila et al. 2007; Nasopoulou et al. 2011; Lordan and Zabetakis 
2017).   
 The association of the Mediterranean diet with a lower incidence of CVD, paired 
with the fact that the most anti-inflammatory and antithrombotic polar lipids can be found 
within defining aspects of the diet has led research to delve deeper into this association. 
Studies have been published that demonstrate the anti-inflammatory properties of olive oil, 
olive pomace (Tsantila et al. 2007), and marine lipid sources (Nasopoulou et al. 2010). A 
separate in vivo study demonstrated that the use of olive pomace in fish feeds improves the 
nutritional value of the fish feed and the fish with improvements to the lipid profile of the 
fish demonstrating the effective implementation and use for valorising this by-product 
(Nasopoulou et al. 2013b).  
 The consumption of dairy products has long been negatively associated with 
cardiovascular health due to the high saturated fat content of dairy foods and the association 
of saturated fats with raised cholesterol levels. This has resulted in a rise in the consumption 
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of low-fat or fat free dairy products in an effort to adhere to dietary guidelines, but evidence 
on the health benefits of dairy products has started to change this perception, with various 
dairy foods exhibiting cardioprotective and anti-inflammatory effects (Dugan et al. 2016; 
Poutzalis et al. 2016; Lordan and Zabetakis 2017). Another aspect of dairy products that is 
being explored is the impact of fermentation on the anti-inflammatory properties of cow, 
goat, and sheep produced yogurts with a study by Lordan et al (2019) demonstrating that 
specific starter cultures can alter the fatty acid composition of the polar lipids and 
antithrombotic properties (Antonopoulou et al. 1996; Tsorotioti et al. 2014; Lordan et al. 
2019c). 
   
1.6.1 Polar Lipids and Alcoholic Beverages. 
 
If fermentation can alter the antithrombotic capabilities of polar lipids in dairy 
products, then the same could possibly be said for fermented beverages as most alcoholic 
beverages are fermented with yeast that have the capability to alter the lipid present in beer 
(Taylor and Kirsop 1977; Buiatti 2008). Another aspect of the Mediterranean diet that differs 
from the western diet is the moderate consumption of wine, predominately red wine, with 
meals. Though many negative connotations surround alcohol due to diseases associated with 
its abuse, studies have demonstrated that when consumed in moderation there can be 
cardioprotective effects (Argyrou et al. 2017; Xanthopoulou et al. 2017).  
 Research into the cardioprotective properties of wine increased when the term 
‘French Paradox’ was used to describe the observation that there was a relatively low-
incidence of CHD among the French population despite their diets being rich in saturated 
fats, which is considered a major risk factor for CVD. The authors suggested that this may 
be attributed to relatively high level of wine intake among the population, an observation 
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similar to that of the Mediterranean diet (Renaud and de Lorgeril 1992). Though the ‘French 
Paradox’ has not been established as a cause/effect relationship, this observation motivated 
research into the relationship between moderate wine consumption and potential 
cardioprotective effects in relation to CHD. Many studies support the moderate consumption 
of wine for its cardioprotective effects due to its microconstituents and ethanol content 
(Fragopoulou et al. 2018; Lordan et al. 2018a). While it is known that excessive 
consumption of alcohol has been linked to a number of chronic diseases (Temple 2012), 
recent research has indicated that alcohol can have a positive impact on cardiovascular 
health when consumed in moderation (20-30g of ethanol for men and 15-20g of ethanol for 
women), potentially displaying a causal relationship between CHD risk and moderate 
alcohol consumption could be the explanation for this (Mathews et al. 2015). The 
relationship between moderate alcohol consumption and reduced CVD risk and all-cause 
mortality is characterised by a J-shaped curve as seen in Figure 1.5 (de Gaetano et al. 2016). 
Apart from lipids, other microconstituents found in wine have been associated with 
cardioprotective effects, such as the inhibitory effects of polyphenols, tyrosol and 
resveratrol, have been shown to exert an inhibitory effect on PAF production and platelet 





Figure 1.5.  A graph that demonstrates the relationship between alcohol intake and relative 
risk of non-fatal cardiovascular events.  
This relationship is characterised by a J-shaped or U-shaped curve (Image reproduced with 
permission from de Gaetano et al 2016)  
 
 The method that is regarded as standard for the analysis of the effect of lipids against 
platelet aggregation is by light transmission aggregometry in platelet-rich plasma (PRP), in 
which lipid fractions, namely the total lipid (TL), total polar lipids (TPL), and total neutral 
lipid (TNL) fractions are analysed for their ability to inhibit or induce platelet aggregation 
in the presence or absence of an agonist such as PAF or thrombin (Tsoupras et al. 2019b). 
Many of these antiplatelet compounds have been found in wine. TL, TPL TNL of wine and 
wine must, which is the unfermented and unfiltered crushed grape juice, were assessed for 
their ability to inhibit PAF-induced platelet aggregation. It was observed that the biological 
activity of the TL and TPL lipid fractions there are more potent in their ability to inhibit 
PAF-induced platelet aggregation, while the TNL do not seem to exhibit strong biological 
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activity. The biological activity of the TL was attributed to the actions of the TPL within the 
TL present (Fragopoulou et al. 2001).  
 A study conducted by Fragopoulou et al (2000) obtained the TPL from Greek red 
wine and further separated the TPL into glycolipids and phospholipids by high-performance 
liquid chromatography (HPLC). Each fraction was tested for their ability to induce or inhibit 
PAF-induced platelet aggregation. The findings of this study demonstrated the existence of 
compounds within the TPL fractions of red wine, some of which exhibit PAF inhibition 
while others antagonise PAF via interactions with the PAF-R (Fragopoulou et al. 2000). The 
use of HPLC analyses in this study allowed a greater insight into the biologically active 
fractions of lipids, with the HPLC yielding fractions of PC, sphingomyelin (SM), lyso-
phosphatidylcholine (L-PC), and PE alongside other glycolipids with all fractions 
demonstrating some degree of biological activity (Fragopoulou et al. 2000). The presence 
of many of these anti-inflammatory polar lipids have been found in other sources such as 
fish (Tsoupras et al. 2019a), and other fermented beverages (Lordan et al. 2019a).  
Though the antithrombotic properties of another fermented product, beer, has not been 
widely reported and it is an area that requires further investigation. It has been demonstrated 
that wine and its by-products such as must contain polar lipids and various microconstituents 
that exhibit potent antithrombotic properties. Therefore, beer and various by-products may 
also possess these bioactive lipids.  A previous investigation into the biological properties 
of the TL, TPL, and TNL of 3 Irish beers, stout, ale, and lager, revealed that the TPL fraction 
of all three Irish beers demonstrated potent antithrombotic properties in vitro further 
suggesting that fermentation may play a role in the formation of these biologically active 
lipids (Lordan et al. 2019a). This study also went on to separate the TPL by thin-layer 
chromatography (TLC) and found polar lipid fractions like those found in other anti-
inflammatory foods like wine, demonstrating the presence of PE, PC, cardiolipin (CL), and 
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SM. These fractions were tested in vitro against PAF-inducing aggregation and 
sphingomyelin, PE, and CL demonstrated promising anti-PAF activities (Lordan et al. 
2019a). 
There is an ever-increasing body of evidence for the associated health benefits of wine 
consumption with very little attention being given to beer. Much of the research conducted 
regarding wine seems to attribute these effects to the effect of ethanol on the lipid profile or 
microconstituents present within the wine, but as demonstrated by Lordan et al (2019a) some 
microconstituents present in wine were also present in the three different beer types that 
demonstrated potent inhibition of PAF-induced platelet aggregation. More research is 
required to assess the bioactivities of beer, its microconstituents, and potential valorisation 
of by-products with regards to cardiovascular health.  
1.7 Brewing and Beer Composition 
The initial brewing of beer has been estimated to extend as far back as 8000 years, but 
it is only with advancements in the underlying science being made over the past 150 years 
or so that brings us to the modernised practice of brewing we are now familiar with 
(Bamforth 2000).  
Ale, stout, and lager are three types of the most popular and common types of beer 
brewed all over the world. These are made using four key ingredients: malted grain 
(Hordeum vulgare), water, hops (Humulus lupulus), and yeast and by varying the 
temperature in the system, yeast strain, grain roasting time and method and time of the hop 
addition can result in many unique types of beer. There are many steps where these 
modifications can take place, however, the process remains relatively consistent following 




Malting is a three-step process and is key to the quality of the fermentation and of the 
beer. This step involves taking harvested grain, be that barley or wheat, and making it 
suitable for the brewing process. This three-step process involves steeping, germination and 
drying. The objective of malting is to increase the water content from ~12% moisture content 
to between 43%-46% moisture content to promote the controlled germination of the barley 
grain (Brookes et al. 1976). During this germination, hydrolytic enzymes are activated by 
the grain that degrade the cell walls and protein, softening the husks for milling while 
subsequently producing the enzymes that will degrade the starch into fermentable sugars for 
the yeast. The final step in malting is kiln drying, which is a heating process designed to halt 
the metabolism of the grain to prevent the germination consuming the starch reserves by 
removing water and making it stable for storage, but also for the purpose of roasting the 
grain to attain a desired flavour, colour, and aroma (Bamforth and American Society of 
Brewing 2006). 
The process of malting makes the grain suitable for the brewing process. The next step 
of the process includes milling and mashing. Milling involves the crushing of the modified 
grain into course, flour like powder known as ‘grist’. This process exposes the modified 
starch reserves and good quality milling allows maximum surface area to contact with water 
which occurs in mashing. The grist is added to a mash tun in the presence of water to dissolve 
the solid matter. The mashing step generally begins at lower temperatures allowing more 
heat sensitive enzymes to continue the enzymatic conversion of polymers before the 
temperature is raised to approximately 65℃ where starch-degrading enzymes such as α-
amylase convert starch to simple, fermentable sugars while proteolytic enzymes  degrade  
proteins and peptides into amino acids to facilitate the growth of the yeast during 
fermentation (Briggs 1962; Bamforth 2014). From this, the sugar rich liquid is separated by 
filtration or lautering to yield the ‘sweet wort’.  
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The sweet wort is boiled to facilitate the removal of undesirable organisms and to 
concentrate the wort before fermentation. Hops are added to the wort during boiling for the 
addition of flavour and aroma by compounds that are released from the hops as they boil. 
As the hops boil, the isomerisation of resins leads to the formation of bitter compounds, 
which are essential to the development of beer flavour, but might also contribute to the 
presence of various phytochemicals (Bamforth 2014). Following filtration and cooling, this 
liquid is transferred to a fermenter for pitching with the yeast. The appropriate yeast is 
selected for the target output. Saccharomyces cerevisiae is known as the ale yeast with 
fermentation occurring at as high as 25℃ and Saccharomyces pastorianus, the lager yeast, 
fermenting at temperatures as low as 6℃ (Bamforth 2000). After the required timeframe the 
pitched yeast will have fermented the maltose and other sugars to ethanol and carbon dioxide 
while also producing other molecules that affect flavour under primarily anaerobic 
conditions (Bokulich and Bamforth 2013). The beer is then subjected to cooling, or cold 
conditioning, for up to 3 days followed by filtration to facilitate the precipitation and 
removal of solids before being packaged into the desired container and shipped to the 
consumer (Bamforth 2000).  
Though the core ingredients remain the same, beer all over the world can vary due to the 
variety of malted grain selected, the temperature used, yeast strain, pH throughout the 
brewing process, the variety, and more importantly method of hop addition, can all have an 
impact on quality and composition of the end product yielding several hundreds of identified 
compounds that contribute to flavour, aroma, texture, foam stability,  and nutritional value 
of beers  (Gerhäuser 2005; Buiatti 2008). Some of these compounds originate in the raw 
materials like the malt and hops while some are the result of yeast metabolism of the 
fermentable sugars. As mentioned it is subject to variations, but the general composition of 
beer is water, ethanol, carbon dioxide, carbohydrates, inorganic salts, organic acids, hop 
26 
 
derivatives, and some B vitamins (Buiatti 2008). The majority of the mineral content of beer 
come from the natural ingredients, with minerals such as calcium, magnesium, potassium, 
sodium, copper, zinc, and manganese being identified in beer samples with many of these 
B-vitamins being crucial to the growth of the yeast originating in the embryo and aleurone 
layer of malted grain (MG) (Muy-Rangel et al. 2018). Other components found in beer such 
as phenolic compounds, esters, aldehydes, ketones, and sulphur compounds also contribute 
in different ways to affect flavours and aromas but too high a level of some of these 
compounds as a result of reactions during the brewing process can cause various undesirable 
end-products (Buiatti 2008). These phenolic compounds are abundant in the human diet 
from sources such as plants, tea, fruits, and vegetables and as discussed, red wine. In beer, 
several polyphenols are derived from the malt (two-thirds) and the hops (one-third) (Buiatti 
2008). As discussed, these polyphenols, such as resveratrol and anthocyanins in wine and 
xanthohumol and its metabolites in beer, could be potential sources of molecules that 
provide cardiovascular protection (Arranz et al. 2012).  
The malted barley is the primary source of the protein, lipids, carbonate, and polyphenol 
compounds in beer. The protein is degraded to peptides and amino acids for use by the yeast 
during fermentation, but some remain in the final product, while the lipid content that is also 
obtained from the malted barley is lost mainly in the spent grain with a very low amount 
retaining in the final product (Buiatti 2008). However, it has been demonstrated that lipids 
extracted from the malt present in wort undergoes modification by the action of yeast during 
fermentation. Medium chain length fatty acids were present in low concentrations in the 
wort, but it was observed that during fermentation, short chain fatty acids were catabolised 
by yeast, which then produced some medium chain length fatty acids, formed by a synthetic 
route as opposed to the degradation of long chain fatty acids (Taylor and Kirsop 1977). This 
is reflected in the GC-MS analysis of three Irish beers; stout, ale, and lager, that found a 
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higher percentage of medium to long chain fatty acid such as 14:1, 16:0, 18:0, 18:1 and 18:2 
in the polar lipid fatty acid composition (Lordan et al. 2019a)  
The concentration of lipid present in any beer is dependent on a few variables such as 
the variety of barley grown (Bravi et al. 2012), the malting conditions, and the mash 
temperature (Evans et al. 2013). The lipid content of barley is approximately 3-4% at the 
beginning but during the malting process there is a loss of lipids during germination due to 
the hydrolysis of some of these triglycerides to free fatty acids (Anness 1984). Once malted, 
~80% of the fatty acids still present are either neutral lipids or free fatty acids, while 
phospholipids and glycolipids make up the remainder (Anness 1984). These phospholipids 
have been identified as PC, PI, and L-PC, where PC and PE were identified as two major 
classes (Hough et al. 1982; Anness 1984). 
The highlighted variables such as growing type and mash conditions makes the fatty acid 
composition of the malt barley, wort, and beer vary in the literature, though the dominant 
fatty acids in the malt, wort, and beer tend to be palmitic acid (16:0), stearic (18:0), oleic 
(18:1), linoleic (18:2), and linolenic (18:3) (Bravi et al. 2012; Gordon et al. 2018). Bravi et 
al (2012) observed that mashing at temperatures over 65℃ can increase the concentration 
of linoleic and linolenic as the higher temperature allows these fatty acids to be absorbed 
from the aleurone layer of the barley that is often not absorbed at the lower temperatures 
(Bravi et al. 2012). The role of lipids in beer has often been associated with adverse effects 
on beer quality with some long chain fatty acids such as the degradation of linoleic and 
linolenic acids to trans-2-noneal being associated with off flavours due to the oxidative 
degradation capabilities (Bravi et al. 2014).  
 Recent research has started to indicate more beneficial roles for lipids, as with other 
ingredients, at the right concentrations. One such role is in yeast metabolism, where long-
28 
 
chain unsaturated fatty acids contribute positively to the activation of yeast cell growth under 
anaerobic conditions, contributing to a quicker fermentation (Bravi et al. 2009). Another 
area where lipids considerably affect beer quality is in foam stability. Beer foam is regarded 
as one of the most important indicators of beer quality, with specific reference being made 
to foam stability where lipids play an important role due to their hydrophobic interactions 
and the foam stability can be affected by fatty acid profile as well as other factors such as 
hop acids, proteins, and polysaccharides (Gordon et al. 2018). Short chain fatty acids such 
as C6-C10 do not disrupt any of the characteristics of beer foams. However, as the length of 
the fatty acid chain increases, the more unstable the beer foam becomes, leading to 
undesirable sensory properties (Wilde et al. 2004). This action is only possible due to the 
ability of lipids to have hydrophobic and hydrophilic interactions, concentrating at surfaces 
with the hydrophilic portion in contact with the aqueous phase of beer and the hydrophobic 
tails interacting with the gas within the bubbles of the foam. This action disrupts protein-
protein interactions by displacing proteins as they are absorbed into the liquid-gas interface 
and it is the competition interaction of these surface-active compounds for places in the 
bubble walls that contributes to foam destabilisation, increasing the chances of coalescence 
of these bubbles until the eventual loss of foam over time (Bamforth 1985).  
Despite being present in beer in such low concentrations, lipids can have positive and 
negative effects on various aspects of beer quality depending on the type of lipids present, 
storage conditions that allow oxidation, and the concentrations present. However, of the 
approximately 3% w/w lipid content of barley, it has been estimated that lipid content in 
beer can be less than 0.1% (Buiatti 2008). This is due to the insolubility of many lipids, as 
evident by their hydrophobic region, the loss of some during malting, and the loss of the 
remainder to the barley by-products of the brewing process called brewer’s spent grain 
(BSG) (Buiatti 2008). BSG is the most abundant of the by-products accounting for 
29 
 
approximately 85% of the total by-products and is the insoluble remains of the mashing 
process, following the removal of the liquid portion, the sweet wort, that contains the 
fermentable sugars for yeast (Mussatto 2014). It is estimated that 20 kg of BSG is produced 
for every 100 L of brewed beer, and due to its high content of undegradable protein (19-30% 
w/w), fibre (30-50% w/w), lipids (~10-13% w/w), and water soluble minerals alongside 
phenolic compounds and it is used as feed for the livestock industry (Buffington 2014; 
Lynch et al. 2016). The composition of brewers spent grain has been analysed with the lipid 
content being majority triglycerides (~55%), free fatty acids (~30%) and phospholipids 
accounting for (5-9%) (Niemi et al. 2012). The fatty acid profile of BSG contains linoleic 
(18:2), palmitic (16:0), and oleic acids (18:1) as the most abundant lipids with lesser amounts 
of stearic and linolenic acid along with the presence of phenolic compounds (Niemi et al. 
2012; Connolly et al. 2013).  
These values can vary as the chemical composition of BSG is subject to change due to 
factors such as malt variety, growing, and harvest conditions and the mashing conditions 
during brewing (Gupta et al. 2010). Interest in the potential use of BSG has grown 
significantly over the past few years, possibly due to economic and environmental pressures 
to reduce the waste we produce and find novel uses for it, which has prompted investigations 
into BSG for its potential to benefit human health, as an ingredient in novel food applications 
and even for energy production such as thermochemical conversion and biogas production 
(Mussatto 2014).   
Spent hops (SPHP) is another by-product of the brewing industry. These occur as part 
of the second solid residue produced during brewing following the boiling of the wort where 
the SPHP along with some other solid residue precipitate such as coagulated proteins that 
were denatured during boiling (dos Santos Mathias et al. 2014). Of the mass of the hops 
used, 85% is disposed. Due to the bitterness compounds present it is not suitable for animal 
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feed as it is not eaten, even when combined with the BSG. Though not much attention has 
been given to the SPHP for potential health benefits, it has been used as a fertiliser or 
compost for farmers with one investigation using essential oils extracted from SPHP as an 
eco-friendly repellent for insects that cause loses of stored foods (Bedini et al. 2015; Kerby 
and Vriesekoop 2017).  
These by-products are produced at such a high rate not only on an industrial level, but 
in addition to this there is approximately 63 craft breweries operating in Ireland as of 2016 
further creating brewing industry wastes. The term craft brewery is defined as a brewery 
involved in the small-scale production (less than 30,000hL) of beer and despite producing 
by-products on a smaller scale than larger industrialised breweries it is still estimated that 
these microbreweries could produce as much as 241,000hL of beer (Flannery Nagel 
Environmental Ltd 2016). The fact that so many by-products are produced with significant 
protein, lipid, fibre, phenolic, and mineral content still within them, the valorisation of these 
by-products for the benefit of human health is a potential route that could be explored 
further.  
 
1.8 Beer and Health 
It is difficult to write about the potential of alcohol-based products as beneficial 
aspects of the diet without discussing the negative impacts excessive consumption can have 
to human health. The harmful effects of alcohol are more known than any beneficial factors 
due to their implications in a variety of chronic diseases such as cancer and obesity (Temple 
2012).  
 Moderate alcohol consumption, mainly from wine, is a key constituent of the 
Mediterranean diet and is associated with improved cardiovascular health (Estruch et al. 
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2018). This is normally consumed with a balanced meal and these beneficial effects have 
been shown in postprandial studies investigating these health effects (Xanthopoulou et al. 
2017). This has been described as the J-shaped curve, or sometimes ‘U-shaped curve’ where 
those who consume 1 or 2 standard drinks per day are at 20-30% reduced CVD risk than 
those who abstain, which is similar to the observations that led to the term ‘French paradox’ 
(Renaud and de Lorgeril 1992; Thompson 2013) 
 The negative effects of alcohol consumption are more associated with over 
consumption of alcohol and in cases of alcohol abuse, but it has been shown to have 
beneficial effects when consumed in moderation with most literature focused on wine due 
to its role in the Mediterranean diet. Beer, though not studied as heavily as wine, has been 
associated with several potential health benefits also (de Gaetano et al. 2016). Moderate 
consumption of alcohol refers to approximately 1-3 units of alcohol and intake at this level 
has been associated with a lower risk of developing CHD (Bamforth 2002; Mathews et al. 
2015). The mechanisms by which alcohol achieves this lower risk of CHD has been 
associated to a number of mechanisms, though it has been demonstrated in several studies 
that alcohol increases the concentrations of serum high-density lipoprotein cholesterol, 
which helps in slowing or preventing the development of atherosclerotic lesions, while other 
authors have credited the cardioprotective properties to its ability to slow or prevent the 
action of PAF during chronic inflammation by competitive displacement or supporting the 
synthesis of molecules that help balance the serum levels of PAF in the body (Thornton et 
al. 1983; Lordan et al. 2019a; Lordan et al. 2019b).  
 In summary, polar lipids from various sources have demonstrated antithrombotic and 
anti-inflammatory effects against a range of chronic diseases that stem from chronic 
inflammation. Many of these polar lipids have been extracted from food and beverages that 
have been observed as components of the Mediterranean diet. Reference was made to wine, 
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cheeses and yogurts as cardioprotective components of this diet with the process of 
fermentation being a core process of many of these cardioprotective foods suggesting that 
fermentation could be a factor in the enhancement of the antithrombotic capabilities of polar 
lipids from these sources.
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Chapter 2:  



















2.1 Chemicals and Reagents  
The experimental procedures conducted as part of this research were lipid extraction, 
thin-layer chromatography (TLC), platelet aggregation analysis, and gas chromatography–
mass spectrometry (GC-MS) with all procedures being carried out at the University of 
Limerick. Glassware, solvents, and chemicals were purchased from Fisher Scientific Ireland 
Ltd. (Dublin, Ireland). All reagents used for platelet aggregation analysis and the lipid 
standards required for GC-MS and TLC analysis, along with the TLC plates were purchased 
from Sigma-Aldrich (Wicklow, Ireland). All platelet aggregometry consumables were 
purchased from Labmedics LLP (Abingdon on Thames, U.K.). All GC-MS consumables 
were purchased from Apex Scientific Ltd (Kildare, Ireland).  
 
2.2 Production of Beer and Origin of Associated Samples 
Munster Brewery (Youghal, Co. Cork, Ireland) provided all the relevant samples for 
this investigation. The beer, an Irish red ale sold by the brewery under the commercial name 
‘12 Towers’ is brewed in accordance with organic certification by the Irish Organic 
Association using only organically sourced materials. All samples investigated were 
associated with the brewing of this Irish red ale from a single production line at Munster 
Brewery with the following controlled parameters.  
 The malted barley used was composed of two barley malts. Organic pale ale made 
up ~70% of the overall malt, which was kiln dried at 90-95℃ providing a base malt while 
the other was 30% was kiln dried to 230℃ yielding a roasting grain. This yields the malted 
barley, the first of the ingredients investigated in this study. Both have a maximum moisture 
content of 4.5% and on the European Brewing Convention (EBC) colour scale, the base malt 
has an EBC colour of between 7 and 10 and the roasting malt an EBC colour between 1,000-
1,400 (Castle Malting Ltd., Beloeil, Belgium) contributing to a unique colour, flavour, and 
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aroma profile in the final product. Only the malted grains and not the raw grains could be 
sourced for this study and the malting process was determined by the company (Castle 
Malting Ltd., Beloeil, Belgium), this is standard for microbreweries. This malted barley was 
milled by the brewery and added to the mash tun where 4L of water was added per kg of 
crushed grain where the steeping process ran at 66℃ for 60 minutes, facilitating the 
conversion of starch to simple sugars. The temperature was then raised to 77-79℃ for 4 
hours as part of the lautering process to denature the active enzymes responsible for this 
conversion of starch to sugars. Following this step, the BSG sample was stored, the first of 
the by-products examined in this study. 
 The liquid phase (referred to as the sweet wort) remaining in the mash tun was then 
transferred to the boiling kettle where the wort was heated to 100℃ and left to boil for 1 
hour. This ensures the sterilization of the wort, denaturation and precipitation of proteins, 
and facilitates the caramelisation of some of the sugars present that contribute to the taste 
and aroma profile of the beer. The second ingredient investigated was the hops. A specific 
amount of organic hops was added (~ 200g/hL) at the beginning of the boil. The hops contain 
many volatile compounds (Aberl and Coelhan 2012) that contribute to the sensory properties 
of the beer. At the end of this process the liquid portion was filtered into the fermentation 
tank by whirlpooling, which yields the second by-product investigated, the SPHP otherwise 
known as the trub. The trub is the name given to the remaining hops and residual grain 
material in the brew kettle after the wort has been filtered into the fermentation tank by 
whirlpooling. This whirlpooling process passes the wort through heat exchangers that cools 
the wort to 20℃, at which point the in-process wort sample was taken, before passing it to 
the fermentation tank.  
 The fermentation was carried out by the yeast Saccharomyces cerevisiae 
(Nottingham High Performance Ale Yeast, Lallenmand Inc., Burton upon Trent, UK), the 
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most commonly used top fermenting yeast. The yeast was pitched into the fermentation tank 
at 80-100g of yeast per hL of wort and the fermentation was let to run for 4 days followed 
by a conditioning period of 7 days at 12℃, and finally 3-4 days at 0-2℃ in a chilling tank 
in a process known as cold crashing, which facilitates flocculation, sinking, and removal of 
the yeast.  
 Once chilling was complete the beer was bottled in the presence of 2g of 100% 
fermentable organic dextrose (Charles Faram Ltd., Worcester, UK) to encourage 
carbonation by any surviving yeast in the beer, this is known as bottle priming. This priming 
occurs for 14 days at room temperature until the desired CO2 levels were achieved (2.2-2.5 
volumes of CO2), following which the bottles were refrigerated (0-4℃) until they are sent 
to the laboratory for testing. The final product is the beer analysed in this study. Samples 
were obtained in triplicate from the highlighted points during different batches of beer 
production in air-tight containers and transported to the University of Limerick where they 
were frozen on arrival for preservation for a maximum of six weeks. 
 
2.3 Extraction 
The lipids were extracted from the brewing materials, by-products, wort, and beer 
from three different batches of beer from the same production line. 
The TL from all samples were extracted in triplicate using the Bligh and Dyer (1959) 
method, which is a method used for the efficient extraction of lipids from a biological 
material (Bligh and Dyer 1959). The TL extraction was achieved by homogenisation of the 
sample in chloroform/methanol/water in a 1:2:0.8 (v/v/v) ratio followed by filtration into a 
separatory funnel. Once filtered the chloroform/methanol/water ratio was adjusted to 1/1/0.9 
(v/v/v) to achieve phase separation with the TL being present in the lower phase. This phase 
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was gathered in a round-bottom flask and evaporated until dry on a rotary evaporator at 40°C 
under vacuum between 700-50 mbar (Buchi Rotavapor, Mason Technology Ltd., Dublin, 
Ireland).  
Once obtained, a tenth of the TL was stored under nitrogen at -20°C. The remaining lipid 
was subjected to a modified method of counter-current distribution of Galanos and Kapoulas 
(1962) whereby pre-equilibrated petroleum ether and 87% ethanol were used to obtain the 
TNL and the TPL extracts, with completion of this method yielding the TPL in the ethanol 
phase and the TNL in the petroleum ether phase within a separatory funnel (Galanos and 
Kapoulas 1962; Karantonis et al. 2008). This modified method, illustrated in Figure 2.1, 
involved dissolving the TL in 10 mL of 87% ethanol. Then, 2 mL of this solution plus 8 mL 
of 87% ethanol was washed through the first separatory funnel containing 30 mL of 
petroleum ether. Phase separation occurs, and the lower phase was extracted into the second 
separatory funnel containing 30 mL of pre-equilibrated petroleum ether to ensure the 
separation of the TNL from the TPL. These steps were repeated several times until all sample 
has been washed through leaving the TPL and TNL in the 87% ethanol and petroleum ether 
phases, respectively. Both phases were collected in round-bottom flasks and evaporated 
using a rotary evaporator until dry. The samples were weighed, and all extracts were stored 
under nitrogen at -20°C until required for further analysis as previously described by 





Figure 6.1. Diagram demonstrating the modified counter-current distribution method using 
increased volumes.  
2 mL of the TL in 87% ethanol solution plus 8 mL of 87% ethanol was added to the first 
separatory funnel. After each addition to the separatory funnel, the funnel was shaken well 
to ensure the maximum interaction of lipids with the solvents. Once phase separation occurs, 
the lower phase was transferred to the second separatory funnel, shaken well and the lower 
phase containing the TPL was extracted to a round-bottom flask. This was repeated until all 
the TL had been washed through leaving the TNL in both separatory funnels dissolved in 
petroleum ether (P.E) which was extracted to a separate round-bottom flask. 
 
2.4 Thin-Layer Chromatography (TLC) 
Phospholipid fractions were obtained by TLC from the TPL of the beer in accordance 
with previously described methods (Nasopoulou et al. 2007; Lordan et al. 2019a). To begin, 
30 mg of dried TPL from the beer was weighed using an analytical mass balance (Sartorious 
Ltd.) and diluted in 100 µL of 1:1 chloroform methanol and applied using a capillary tube 
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to the TLC plate evenly along the bottom of the silica plate. Along the same level, but 
separated from the beer TPL, a phospholipid standard from eggs purchased from Sigma-
Aldrich (Wicklow, Ireland), against which the fractionated bands were compared by their 
retention factors (Rf). Once the sample was placed on the TLC plate, the plate was placed in 
an elution tank containing the mobile phase of chloroform, methanol, and water in the ratio 
of 65:35:6 (v/v/v). As capillary action caused the mobile phase to move up the TLC plate, 
fractions of phospholipids were eluted from the solution at different times dependant on their 
affinity to the stationary phase or mobile phase caused by their polarity. Once the solvent 
front had reached the end point, as seen by the uppermost pencil line on the plate, as seen in 
Figure 9, the TLC plate was removed and from the elution tank and placed in the fume hood 
to dry, allowing the evaporation of all solvents before staining. Phospholipids were stained 
using iodine vapours for visualisation of individual lipid fractions on the plate, the distance 
travelled by each fraction was marked and compared to the egg standard for identification. 
Once iodine vapours had evaporated, lipid fractions were scraped from the plate and 
extracted from the silica gel using the Bligh & Dyer (1959) method. The chloroform phase 
of the extraction containing the isolated polar lipids were evaporated to dryness under 
nitrogen, weighed as previously described, and re-dissolved in chloroform:methanol 1:1 
(v/v) and stored in sealed vials in the presence of nitrogen at -20℃ and stored for a maximum 
of six weeks, until required for further analysis.  
 
2.5 Aggregometry 
The in vitro assessment of PAF-induced platelet aggregation was carried out as 
described in several publications (Nasopoulou et al. 2007; Lordan et al. 2019a; Fragopoulou 
et al 2000). The protocol was performed in accordance with Declaration of Helsinki, 
following approval of the protocol by the Ethics Committee of the University of Limerick.  
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An overnight fasting blood sample was collected from healthy volunteers (n=12) that 
were not undergoing any form of antiplatelet treatment. The donors gave written consent 
and were fully aware of the designated use of the blood samples during the study. The blood 
was withdrawn via venepuncture of the median cubital vein using a technique known as the 
aspiration method by a clinical nurse using a 20G needle into evacuated sodium citrate S-
monovettes (0.106mol/l in a 1:10 ratio of citrate to blood; Sarstedt Ltd., Wexford, Ireland) 
where the sodium citrate acts as an anticoagulant (Lordan et al. 2019c).  
The S-monovettes were subjected to centrifugation at 18 x g for 18 minutes at 24℃ 
(Eppendorf 5702 R, Eppendorf Ltd, Stevenage, UK) and the platelet-rich plasma (PRP) was 
removed. This was followed by a subsequent centrifugation at 1,500 x g for 20 minutes at 
20℃. No brake was applied to either centrifugation to prevent platelet activation. The first 
centrifugation contains the PRP, which formed at the top layer of the S-monovette. This PRP 
was transferred to a polypropylene tube to be used during the aggregation bioassay while 
the second centrifugation of the S-monovette allows the isolation of the platelet-poor plasma 
(PPP) that was used as a blank. The PRP was standardised to 500,000 platelets µL-1 by 
diluting the PRP with PPP until an absorbance of 0.8 was achieved at 530 nm using a 
Shimadzu UV-1800 spectrophotometer (Kyoto, Japan) prior to analysis on a Chronolog-490 
two channel platelet aggregometer (Havertown, PA, USA), coupled to the AGGRO/LINK 
software package.  
Lipid samples (TL, TPL, and TNL) and PAF were prepared prior to testing, dissolving 
them separately in a solution of Bovine serum albumin (BSA)-saline (2.5mg BSA/mL 
saline). The PAF concentration in the cuvette was 2.6 x 10-8. The lipid samples were 
prepared by dissolving them in known concentrations of BSA (2.5mg BSA/mL saline). 
Various concentrations of the sample can be added to the platelet bioassay via the following 
method to assess the sample ability to inhibit PAF-induced platelet aggregation. 
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Once all samples were prepared, 250 µL of PRP was added to an aggregometer cuvette 
at 37℃ with stirring at 1,000 rpm and was calibrated using the PPP as a blank to represent 
0% platelet aggregation. PAF was then added to the cuvette, inducing aggregation of 
platelets in order to calculate the maximum reversible aggregation (~2.6x 10-8 M, final 
concentration in cuvette) and 50% PAF-induced aggregation. The PAF-induced aggregation 
was calculated at a range of PAF concentrations to obtain a linear curve with this IC50 value 
being calculated as described by Tsoupras et al (2018a). The IC50 value is the concentration 
of sample that induces 50% of PAF-induced platelet aggregation. The PAF curve is used to 
calculate this IC50 value in triplicate (n=3) with a different healthy blood donor for all lipid 
samples along with the TPL fractions obtained by TLC and expressed as a mean value of 
the mass of lipid (µg) in the cuvette ± standard deviation (SD). Different concentrations of 
lipid samples (measured in µg) were added to the platelet suspension and the ability of each 
to inhibit PAF-induced aggregation was recorded. All samples were tested on the blood 
within 3 hours of venepuncture.  
 
2.6 Gas Chromatography-Mass spectrometry (GC-MS) 
Using approximately 35mg of TPL, fatty acid methyl esters (FAME) were prepared 
for the beer, wort, brewing ingredients, and by-products similarly to that of the preparation 
of Tsoupras et al (2018a). The FAME method was employed for the rapid derivatisation of 
fatty acid methyl esters using a 90% solution of 0.5M KOH CH3OH and subsequent 
extraction using hexane. To do this, 1 mL of n-hexane and 4 mL of the 90% KOH solution 
were added to a test tube, vortexed well and, using hydrochloric acid (HCL) and the KOH 
solution, adjusted to pH 7. At pH 7, phase separation occurs with the addition of 2 mL of 
H2O and 2 mL of n-hexane to the solution. The fatty acids orientate to the upper phase, 
which is then extracted into another clean test tube using a glass Pasteur pipette. Once again 
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2 mL of n-hexane is added to the original test tube, vortexed, and the upper phase is again 
transferred to the second test tube. The FAME is extracted following the addition of 2 mL 
of H2O to the second test tube and rejection of the lower phase. The obtained fatty acid 
methyl esters were dried under nitrogen and weighed before being dissolved in 90 µL of 
hexane and 10 µL of the 21:0 (2000ppm) internal standard. 
The GC-MS analysis was carried out similarly to that described by Tsoupras et al 
(2018a), by using the internal standard method and was conducted using an Agilent J&W 
DB-23 fused silica capillary column (60 m, ‘0.25 mm i.d.’ 0.25 µm f.t.; Agilent 
Technologies Ltd., Santa Clara, CA, USA). A five-point calibration curve was prepared 
using five solutions of heptadecanoic acid methyl esters (17:0 at 50ppm, 100ppm, 200ppm, 
400ppm, and 800ppm) and five 500ppm injections of heneicosanoic acid (21:0) methyl 
esters on a Varian 410-Gas Chromatographer coupled to a Varian 210-MS detector equipped 
with a split/splitless injector (Agilent Technologies, Pal Alto, CA, USA). The Calibration 
curve describes the line as y = 0.0041x + 0.12 with an R2 of 0.9969, visible in the appendices 
as Figure 8, where the ratio of 17:0 to 21:0 is represented by the y-axis variable, while the 
concentration (ppm) of 17:0 represents the x-axis variable of the calibration curve. Using 1 
µL injections, this equation was used to find the concentrations of fatty acids within the lipid 
sample where the ratio of the area of the analyte peak to that of the internal standard peak is 
this time representing the y-axis value, while the x-axis value represents the analyte 
concentration of the fatty acid associated with the peak selected.  
Injection of 1 µL into the Varian 410-GC set at 230℃ with a split ratio of 1:20 begins 
the separation process. The flow rate of the carrier gas, high purity helium, was set to 1 
mL/min, the oven temperature was initially set to 100℃ for 5 minutes, rising to 240℃ at a 
rate of 3℃/min and finally isothermal at 240℃ for 10 minutes. The retention time, mass 
spectra, and peak area of the fatty acids were obtained. These values were used to identify 
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the FAME when they were compared to a pre-derivatised 37-component FAME standards 
mix (Sigma Aldrich, Wicklow, Ireland), which allowed for identification of fatty acids 
within the analyte by comparison of their retention times and mass spectra of these peaks. 
Varian Star Chromatography Workstation Version 6 software (Aglient Technologies, Palo 
Alto, CA, USA) and a NIST library of mass spectra (Gaithersburg, MD, USA) was also used 
to aid the identification of fatty acids.  
 
2.7 Statistical Analysis   
All experiments were completed in triplicate with the obtained results expressed as a 
mean value ± standard deviation (SD). These values were obtained using one-way analysis 
of variance (ANOVA) and the Kruskal-Wallis non-parametric test to determine significant 
statistical differences between analyses if present for all data except for the analyses of the 
GC-MS data where one-way analysis of variance (ANOVA) and the Tukey’s honest 
significant difference (HSD) multiple comparison post-hoc test was used (SPSS Inc., 



































The TL was extracted in triplicate (n=3) from three separate samples of the beer, wort, 
and the grain and hop ingredients and by-products. The TL of these samples were separated 
to TPL and TNL. These results are displayed on Table 3.1 expressed as g of lipids per 100g 
of sample, with the TPL and TNL also being displayed as a percentage of the TL. 
 
Table 3.1. The Total lipid (TL), total neutral lipid (TNL) and total polar lipid (TPL) 
expressed as g/100g of sample with TNL and TPL also being expressed as a percentage of 
TL (mean ± SD, n=3) 
 TL (g/100g) TNL (g/100g) TNL (% TL) TPL (g/100g) TPL (% TL) 
MG 0.70 ± 0.10a 1.03 ± 0.03a 13.6 ± 2.9c 0.52 ± 0.05a 74.5 ± 3.5b 
BSG 1.05 ± 0.19a 0.55 ± 0.11b 52.6 ± 2.5e 0.41 ± 0.09a 38.9 ± 2.3a 
RWHP 14.17 ± 2.18b 1.63 ± 0.31c 11.5 ± 3.7bc 11.6 ± 1.68b 79.4 ± 8.6b 
SPHP 0.75 ± 0.06a 0.16 ± 0.01a 21.4 ± 3.0d 0.55 ± 0.07a 72.6 ± 4.1b 
Wort 0.03 ± 0.002a 0.002 ± 0.001a 5.4 ± 1.6ab 0.03 ± 0.001a 84.5 ± 8.9bc 
Beer 0.02 ± 0.004a 0.0003 ± 0.0001a 1.7 ± 0.4a 0.02 ± 0.005a 91.3 ± 2.7c 
a,b,c,d,e are superscripts used to indicate significant differences among different lipid 
extracts within the same lipid class (p < 0.05) when samples are compared using 
Kruskal-Wallis non-parametric test. Abbreviations: MG = malted grain; BSG = 
brewer’s spent grain; RWHP = raw hops; SPHP = spent hops. 
   
 The amount of TL obtained from the MG and the BSG was low and it can be seen 
that the TPL accounts for a large portion of the TL present within the MG. It was observed 
that the TNL makes up a larger proportion of the BSG than the MG. The raw hop (RWHP) 
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sample has a significantly higher TL than all other samples with a large proportion of this 
being TPL. After boiling, a significant reduction can be seen in the quantity of TL in the 
SPHP from the RWHP though the relative amount of TPL in the TL is still similar to the 
RWHP. The quantity of lipids extracted from the ingredients into the wort and beer is 
significantly lower with TPL accounting for large proportions of the TL as is in accordance 
with the literature (Bravi et al. 2014; Lordan et al. 2019a).   
3.2 Aggregometry 
The antithrombotic activity of the TL, TNL, and TPL of samples are presented in 
Table 3.2. Each sample was measured for their ability to inhibit PAF-induced platelet 
aggregation in vitro with the results being presented as the IC50, a measure of the mass of 
lipid, in micrograms (µg), that is required to induce half maximal-reversible aggregation via 
interactions with PAF or PAF-R in the PRP, meaning a lower value IC50 is an indication of 
high inhibitory action against PAF-induced human platelet aggregation. The TL of the MG, 
RWHP, and SPHP showed moderate levels of inhibitory activity against PAF while the TL 
of the BSG, wort, and beer showed high levels of inhibition against PAF-induced platelet 
aggregation. In many cases, the biological activity of the TL could be attributed to the action 
of the TPL. However, in the BSG the TL displayed potent inhibitory action against PAF 
despite the TNL and TPL displaying much lower biological activity. This is unusual, but 
this could be attributed to synergistic action of the TPL and TNL of the BSG. However, 
further research is required. 
The inhibition of the TPL and TNL extracted from the TL also displayed inhibitory 
action against PAF-induced platelet aggregation. Of the TNL examined in the bioassay, MG, 
wort and beer were the only extracts that exhibited any significant biological activity 
towards PAF with moderate levels of inhibition. Moderate-low biological activity was 
induced by the TPL of the samples tested with the exception of wort and beer. The wort 
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displayed a strong inhibitory action towards PAF displaying a low IC50. The TPL of the beer 
displayed the most inhibitory action against PAF-induced platelet aggregation with a very 
low IC50 result being observed which is in accordance with literature (Lordan et al. 2019a). 
The increase in biological activity between the wort and beer TPL highlights that 
fermentation affects the biological activity of the lipids, which was statistically significant 
(p < 0.05) when the wort and beer were compared using Kruskal-Wallis non-parametric test. 
 
Table 3.2. The in vitro antithrombotic properties of the TL, TNL and TPL of all samples 
against PAF-induced platelet aggregation. The results are presented as mean IC50 value in 
micrograms (µg) ± SD (n=3). 
 TL TNL TPL 
MG 495 ± 105c 298 ± 89a 191 ± 58c 
BSG 69 ± 33b 610 ± 136c 617 ± 184d 
RWHP 453 ± 109c 1088 ± 172c 473 ± 280cd 
SPHP 519 ± 81b 924 ± 166bc 436 ± 142cd 
Wort  70 ± 29b 175 ± 61a 58 ± 11b 
Beer 6.4 ± 4.5a 248 ± 66a 7.8 ± 3.9a 
a,b,c Different subscripts indicate significant differences among different lipid extracts within 
the same lipid class (p < 0.05), when samples are compared using Kruskal-Wallis non-
parametric test. Abbreviations: MG = malted grain; BSG = brewer’s spent grain; RWHP = 
raw hops; SPHP = spent hops. 




The TPL of beer was fractionated by TLC, the isolated bands scrapped, extracted by 
a modified method of Bligh & Dyer (1959), dried, and the mass was determined using an 
analytical mass balance (Sartorius UK Ltd., Epsom, UK). These fractions were then 
subjected to examination in the bioassay. Bands 1 and 7 displayed poor inhibition against 
PAF. Some moderate antithrombotic activity was shown by bands 4 and 5. A low IC50 value 
was displayed by band 6 showing potent PAF-inhibition, though it was bands 2 and 3 that 
displayed very potent biological activity against PAF-induced platelet aggregation with very 
low IC50 values as can be seen in Table 3.3. Figure 3.1 displays the antithrombotic activity 
of the isolated bands from the beer TPL relative to each other, highlighting the potent 
antithrombotic nature of the lipid fraction isolated from bands 2 and 3.  
 Table 3.3. The in vitro antithrombotic properties of Beer TPL lipid fractions from beer 
against PAF-induced platelet aggregation. Results are presented as mean IC50 value in 
micrograms (µg) ± SD (n=3). 
 Band 1 Band 2 Band 3 Band 4 Band 5 Band 6 Band 7 





 Figure 7.1. The mean IC50 (μg) values for the TPL bands of the beer isolated using TLC 
with error bars of standard deviation (mean ± SD, n = 3).  
A photograph of the stained TLC plate prior to the isolation of fractionated bands is visible 
in the appendices, Figure 9. The beer sample was placed in the middle lane and the egg 
standard was placed on both outermost lanes for reference. 
 
3.3 Thin-Layer Chromatography  
Using TLC, the beer TPL was split into their phospholipid subclasses and the Rf values 
were obtained. This was done by measuring the distance travelled by the phospholipid 
fraction and dividing it by the distance by the solvent front. The Rf values of the beer were 
obtained and compared with the Rf values of the standard which are L-PC, SM, PC, PE and 
CL. Rf values similar to that of the egg standard were recorded along with two unidentified 
bands. PC and PE were the most visible on the TLC plate indicating a higher presence of 
unsaturated fatty acids in these bands. (Arranz et al. 2012; Lordan et al. 2019a). Seven bands 
were scrapped from the plate and isolated for testing in the bioassay, the results of which are 
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displayed in Table 3.3 as IC50 (µg) values. The TLC plate prior to the removal of the 
fractionated TPL can be seen in the appendices as Figure 9. 
3.4 GC-MS 
The fatty acid composition of the TPL of all samples was investigated and the results 
are displayed in Table 3.4. The fatty acid profile displayed in Table 3.4 though these fatty 
acid profiles are associated with the brewing of this particular red ale. As mentioned, 
growing conditions and variety of the barley, method of hop addition and fermentation 
variables can all alter the fatty acid profile, which can cause different beers to have different 
fatty acid profiles which has previously been shown in 3 beer varieties (Lordan et al. 2019a).    
The most abundant fatty acids found in the TPL were 18:3, 18:2, 18:1, 18:0, and 16:0 
which is similar to that what is known of the fatty acid profile of the lipid composition beer, 
wort and barley in general (Evans et al. 2013). Some significant changes can be observed 
between the ingredients and their associated by-products. Statistically significant differences 
were observed in the percentage of some fatty acids between samples in the TPL. In the MG 
and BSG, there was a significant rise in the percentage of fatty acids such as 16:0, and 18:1 
t13 but a reduction in the percentages of 18:1 c9, 18:2 along with the absence of some short 
chain fatty acids in the BSG that were detected in low amounts in the MG such as 22:0, 22:1 
and 22:6.  
In the SPHP, a statistically significant rise was observed when compared to the RWHP 
sample in the percentage of numerous fatty acids, but the most notable was a rise in the 
percentage of 16:0, 18:1 c9, and 18:2 c9 c12. Some of the large changes observed could be 
associated with the potential presence of proteins and other by-products that are precipitated 
and removed during the boiling. Detection of several phytochemicals was also observed, 
listed in Table 3.4, with the largest proportions being observed in the RWHP with low 
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percentages of phytochemicals being observed in the final product. Of the additional 
volatiles detected in the beer, 1.1% was attributed to hexanedioic acid (also known as adipic 
acid E355). The exact source of the adipic acid is unknown as it was not an intentional 
additive to the product.  
The fatty acid profile of the TPL of the beer and wort was also examined with most of 
the statistical difference in the fatty acids occurring from reduction in the percentages of 
18:0, 18:1 c9, 18:1 t13, 18:2 c9 c12 and 18:3 c9 c12 c15 in the TPL. These reductions were 
accompanied by a significant increase in the percentage of 20:4 present in the beer despite 
this fatty acid not being detectable in the grain or hops. The changes in the fatty acid 
composition of the wort and beer are noteworthy when considering that fermentation is the 
only process that happens between these two samples in the brewing process, highlighting 
further the potential effect of fermentation on the fatty acid profile.   
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Table 3.4. Fatty acid and phytochemical composition of brewing ingredients and by-products, wort, and beer. Results are presented as 
percentage of detected volatile compounds (mean ± SD, n=3) 
Fatty acids Malted Grain Brewer’s Spent Grain Raw Hops Spent Hops Wort Beer 
8:0 ND ND 0.035 ± 0.009 b 0.023 ± 0.007ab 0.013 ± 0.004a ND 
10:0 ND ND 0.055 ± 0.003b ND 0.013 ± 0.004a 0.017 ± 0.005a 
12:0 0.165 ± 0.016d ND 0.023 ± 0.002a 0.026 ± 0.006a 0.090 ± 0.009c 0.068 ± 0.003b 
12:1 ND ND 0.048 ± 0.006 ND ND ND 
14:0 0.615 ± 0.059b 0.688 ± 0.064b 0.334 ± 0.053a 1.043 ± 0.106c 1.584 ± 0.040d 1.547 ± 0.094d 
14:1 ND 0.412 ± 0.114 ND ND ND ND 
15:0 0.309 ± 0.036a 0.224 ± 0.072a 0.493 ± 0.138b 0.249 ± 0.010a 0.169 ± 0.015a 0.160 ± 0.018a 
16:0 19.83 ± 0.928a 27.86 ± 0.802b 22.05 ± 1.230a 30.38 ± 0.955c 31.80 ± 0.599c 32.34 ± 0.683c 
16:1 0.385 ± 0.037a 0.295 ± 0.120a 2.354 ± 0.295c 1.147 ± 0.153b 0.604 ± 0.015a 0.333 ± 0.205a 
17:0 0.176 ± 0.015a ND 1.226 ±0.032d 0.456 ± 0.031c 0.241 ± 0.019b 0.226 ± 0.013ab 
17:1 0.087 ± 0.014a ND 0.746 ± 0.035d 0.356 ± 0.026c 0.203 ± 0.014b 0.203 ± 0.034b 
18:0 2.628 ± 0.621ab 2.231 ± 0.250a 2.846 ± 0.083abc 3.854 ± 0.175d 3.610 ± 0.091cd 3.324 ± 0.103bcd 
18:1 c9 9.042 ± 0.186d 8.813 ± 0.440d 4.387 ± 0.106a 6.670 ± 0.257d 6.118 ± 0.242bc 5.617 ± 0.179b 
18:1 t13 0.657 ± 0.024a 1.009 ± 0.093ab 1.271 ± 0.159bc 1.815 ± 0.242d 1.415 ± 0.089c 1.263 ± 0.136bc 
18:2 c9 c12  56.67 ± 0.770e 51.83 ± 1.592d 25.46 ± 1.471a 40.68 ± 0.344b 44.78 ± 0.063c 43.38 ± 1.554bc 
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18:3 c6 c9 c12  ND ND 0.575 ± 0.016b 0.117 ± 0.012a ND ND 
18:3 c9 c12 c15 6.802 ± 0.954abc 5.856 ± 0.540ab 23.42 ± 1.433d 8.829 ± 0.918c 7.720 ± 0.712bc 5.132 ± 0.256a 
20:0 0.583 ± 0.103ab 0.781 ± 0.172bc 1.022 ± 0.042c 0.482 ± 0.069a ND ND 
20:1 c13 ND ND 0.254 ± 0.054a 0.538 ± 0.035c 0.386 ± 0.019b ND 
20:2 c11 c14 ND ND 1.002 ± 0.052c 0.493 ± 0.073b 0.268 ± 0.014a 0.306 ± 0.038a 
20:4 c5 c8 c11 c14 ND ND ND ND 0.519 ± 0.056 4.929 ± 0.019 
20:5 c5 c8 c11 c14 c17 ND ND  0.527 ± 0.009b 0.164 ± 0.027a 0.408 ± 0.100b ND 
22:0 0.295 ± 0.0037a ND 1.317 ± 0.315c 0.719 ± 0.127b 0.413 ± 0.019ab 0.288 ± 0.067a 
22:1 0.318 ± 0.085a ND 0.410 ± 0.057a 0.335 ± 0.089a ND ND 
22:6 c4 c7 c10 c13 c16 c19 0.469 0.087a ND 1.460 0.169b 0.433 0.129a ND ND 
∑SFA 24.43 0.704a 31.79 0.940b 29.40 1.324b 37.23 0.909c 37.94 0.599c 37.97 0.544c 
∑MUFA 10.67 0.141c 10.53 0.411c 9.469 0.483b 10.86 0.302c 9.133 0.209b 7.416 0.448a 
∑PUFA 63.95 1.53c 57.69 1.090b 52.87 2.657a 50.71 0.673a 53.69 0.589a 53.75 1.761a 
Phytochemicals       
Hexanedioic acid ND ND ND ND 0.277 0.042 1.128 0.208 
Aromadendrene oxide ND ND 1.769 0.391 0.105 0.018 ND ND 
2,4-Di-tert-butylphenol ND ND ND ND ND 0.120 0.012 
Β-Carophyllene ND ND 2.020 0.371b 0.365 0.047a ND 0.069 0.006a 
2-Dodecanone  ND ND 0.066 0.048 0.042 0.008 ND ND 
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Cubenol ND ND 0.237 0.177 ND ND ND 
Tau-Cadinol  ND ND 0.142 0.076 ND ND ND 
Tau-Muurolol ND ND 0.293 0.024 ND ND 0.075 0.003 
∑Phytochemicals ND ND 8.901 0.319b 0.9490.322a ND 1.374 0.217a 
a,b,c,d,e  are subscripts used to indicate significant differences between lipid compositions. Different letters in the same row indicate statistically 
significant difference between the same compound in different samples when mean values ± SD (n=3) are compared using Tukey’s HSD multiple 
comparison test (p < 0.05). Abbreviations: MUFA = monounsaturated fatty acids; ND = non-detectable; PUFA= polyunsaturated fatty acids; SFA= 










4.1 Introduction to discussion 
CVD will remain the top global cause of death if measures are not taken to prevent its 
development. One such measure is developments in the wealth of knowledge of food and 
beverages that are natural sources of cardioprotective compounds. The anti-inflammatory 
properties polar lipids have been explored in several sources including fish (Nasopoulou et 
al. 2011), olive oil and pomace (Karantonis et al. 2008), dairy products (Lordan and 
Zabetakis 2017), and fermented beverages such as wine (Fragopoulou et al. 2001) and beer 
(de Gaetano et al. 2016; Lordan et al. 2019a). It has also been shown that phenolic 
compounds can co-migrate with polar lipids during extraction, as has been demonstrated by 
the presence of 2,4-Di-tert-butylphenol. While it has been shown that polar lipids can inhibit 
the PAF-induced platelet aggregation in vitro, the mechanism for the antithrombotic of 
phenolic compounds has not yet been discovered (Tsoupras et al. 2018b). However, studies 
that have fractionated the TPL of samples and tested their antithrombotic properties against 
PAF have helped give some insight into the nature of the interactions of certain phospholipid 
classes with PAF or the PAF-R (Tsorotioti et al. 2014; Lordan et al. 2019a). The aim of this 
study was to investigate the antithrombotic properties of lipid brewing ingredients, by-
products, wort, beer and beer TPL lipid fractions. The fatty acid composition of the TPL of 




The TL, TNL and TPL were extracted from the malted grain (Hordeum vulgare), hops 
(Humulus lupulus), wort and beer for analysis. Previous research has investigated the TPL 
of 3 types of Irish beer finding ale to possess the most antithrombotic activities against PAF-
induced platelet aggregation when compared with stout and lager (Lordan et al. 2019a). To 
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extract the lipids from the samples intact, the method of Bligh & Dyer (1959) was used. 
While this method may not be the most efficient extraction of the TL, as it does not use harsh 
acids, heat treatment, or hot alcoholic extractions associated with some other methods 
(Morrison and Coventry 1985), the Bligh & Dyer (1959) method allows for the rapid 
extraction of the bioactive lipids, allowing further analysis in subsequent steps with reduced 
risk of the decomposition of some fatty acids compared to harsher methods that employ high 
heat.  
 The lipid content of barley is reported at ~3% (w/w) of dry weight in living tissues, 
however it is estimated that 30% of these are lost during malting due to the hydrolysis of 
triglycerides to free fatty acids (Anness 1984; Buiatti 2008). This means that a barley sample 
prior to malting would be estimated to have TL in the region of 3g/100g and after malting it 
would be ~2.1g/100. TL extracted from the MG was much lower (0.7g/100g) than these 
figures but these lipids can be difficult to extract from barley before or during malting. Up 
to 33% of the lipid content is located within the aleurone layer and starch granules of barley, 
often not being extracted at lower mashing temperatures and being lost to the BSG 
(MacLeod and White 1962; Evans et al. 2013). Other lipids and fatty acids may form 
interactions with polysaccharides in the barley leaving them tightly bound to starch in the 
form of amylose-lipid complexes until it is degraded to fermentable sugars, making them 
difficult to extract prior to milling and mashing without using the heat or acid intensive 
extraction (Marion et al. 2003; Gordon et al. 2018). The weight of the TL extracted from 
the BSG was higher, though not statistically significant than the MG, though the TPL of 
BSG displayed a statistically significant lower percentage of TPL (38.9% of TL) than that 
of the MG (74.5% of TL). This is in accordance with literature as the BSG has been subjected 
to milling and mashing, during which endogenous lipase activity causes the release of free 
fatty acids from these triglycerides and phospholipid (Niemi et al. 2012).  
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 The RWHP sample demonstrated a TL that was significant from the TL of all other 
samples by weight (14.7g/100g) as observed in Table 3.1. However, the hops used in the 
brewing of this red ale were added to the brew kettle in the form of pelleted hops. These 
pelleted hops are highly concentrated and accounts for the high TL content observed in Table 
3.1. The role of hops in brewing is to contribute aroma and bitterness compounds to enhance 
the sensory profile of the beer and it does this through the release of oils into the wort during 
the boiling step (Lermusieau and Collin 2004). The boiling step is a very energy intensive 
process and various measures are taken to reduce costs. An example of this is seen in this 
brewery by the use of condensed hop pellets as opposed to the air-dried female hop flowers. 
The fatty acid content of air-dried female hop flowers is ~1-2%, the essential oil content is 
~0.5-3% and waxes and steroids can range from trace amounts to 25% (Shinohara et al 2000; 
Almaguer et al. 2014). The compounds desired for the product make up a low percentage of 
the hop flower and many of the oils are volatile compounds and are lost to evaporation 
during boiling. This leaves only some of the hop oils to make it intact to the wort, while 
others can still remain in the SPHP as seen in the GC-MS data on Table 3.4. These oils make 
up 0.5-3% of the dry weight of the hops, but within that over 400 hop aroma components 
have been identified (Sharpe and Laws 1981; Aberl and Coelhan 2012; Almaguer et al 
2014), so the usage of hops condensed into pellet form to raise the concentration is a practical 
move by breweries. As previously mentioned, during boiling the hydration of the condensed 
hop pellets allows the passing of many of the compounds present in the hops to the wort 
where many are lost in evaporation and some remain in the wort. This aids in explaining 
why the TL content of the SPHP (0.75g/100g) was observed to be much lower than that of 
the RWHP (14.17g/100g), as per Table 3.1. 
 There were no statistically significant differences observed between TL of the wort 
(0.03g/100g) and the beer (0.02g/100g), with both samples yielding considerably low 
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amounts of TL, which is in accordance with the available literature as much of the lipid 
content of barley is lost to the BSG (Anness 1984; Lordan et al. 2019a). The low lipid 
content could also be attributed to filtration steps employed by some breweries such as 
whirlpooling and the cold crashing method employed by this brewery. These filtration steps 
are aimed at the removal of proteins and polyphenol compounds, of barley and hop origin, 
that can interact with one another to contribute to beer chill haze, a limiting factor to the 
shelf life of a beer (Loch-Ahring et al. 2008). The use of these methods highlights just some 
of the various methods breweries employ for the clarification of the wort and beer, through 
which a reduction in the lipid content could also be targeted as lipids are associated with the 
destabilisation of the beer foam (Wilde et al. 2004). 
 
4.3 Aggregometry 
The biological activity of the TL, TPL and TNL of all samples was investigated in 
vitro against the action of PAF-induced platelet aggregation in human PRP with the results 
displayed in Table 3.2, while the same activities were investigated in isolated lipid fractions 
obtained from the TPL of beer using TLC and are displayed in Table 3.3 and Figure 3.1. All 
results are expressed as IC50 which is described as the mass of lipid in micrograms (µg) that 
is required to induce half the maximal-reversible aggregation caused by PAF-induced 
platelet aggregation (Lordan et al. 2019a).  
The TPL of MG showed moderate-low levels of inhibition. However, the MG TPL 
performed better than both the TPL and TNL of the BSG. An interesting observation from 
these results is that the TL of the BSG displayed an IC50 that was statistically significantly 
lower when compared to the TPL and TNL of the same sample. The TPL and TNL of the 
BSG displayed very poor levels of inhibition though the TL of the BSG displayed strong 
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inhibitory action against PAF as can be seen in Table 3.2. These results could suggest a 
synergistic interaction between the TPL and TNL that improves their ability to interact with 
PAF/PAF-R that each class of lipid cannot achieve independently which has been suggested 
previously (Lordan et al. 2019a) though further investigation is warranted. Therefore, due 
to the potent biological activity of the BSG TL, further investigation is warranted for the 
valorisation of the BSG. The valorisation of BSG has been extensively studied and is 
currently used in energy production and chemical processes (Mussatto 2014), as well as a 
novel growth medium for yeast (Cooray et al. 2017). Furthermore, the presence of 
cardioprotective components found in the TL of BSG suggests the potential for another use 
of this by-product in the development of nutraceuticals or functional-foods should they 
successfully be isolated from the BSG possibly by food-grade extractions (Tsoupras et al. 
2019a). The use of by-products for nutraceuticals or animal feed to improve its lipid profile 
has previously been demonstrated by the olive industry (Sioriki et al 2016) and highlights 
the potential for BSG to be used in a similar manner due to its availability and low cost 
(Lynch et al 2016). 
 The RWHP and SPHP displayed poor antithrombotic activity with the best of these 
samples being the TL of the RWHP. However, the TPL of the RWHP displayed similar 
antithrombotic activity to the TL, while the TNL displayed very poor activity against PAF 
activity, which suggests that the of antithrombotic activity of the RWHP TL can be attributed 
to the TPL that comprises ~79.4% of the TL, as per Table 3.1. The SPHP samples displayed 
similarly low biological activity against PAF with the TPL displaying a non-statistically 
significant lower IC50 than the TL. As previously mentioned, these SPHP samples are 
collected after the boiling step and resultingly the SPHP sample will have lost many of the 
volatile compounds to evaporation or to the wort resulting in little bioactivity in the hops.  
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 A significant amount of activity was seen in the wort and beer against the action of 
PAF-induced platelet aggregation with the TL and TPL of both samples showing particularly 
low IC50 values, as per Table 3.2, which is in agreement with literature (Lordan et al. 2019a). 
The Kruskal-Wallis non-parametric test was used for all statistical difference tests of the 
blood analyses and showed a statistical difference between the beer and wort with a 
significant increase in the antithrombotic activity of the beer when compared to the wort. 
This indicates that there is a change in the TPL composition of the wort when it is fermented 
to beer. This is in accordance with studies that have also observed an increase in the 
antithrombotic capabilities of lipids after fermentation, suggesting a possible role for 
fermentation in the biosynthesis or activation of potent antithrombotic compounds (Lordan 
et al. 2019c). The antithrombotic activity of the wort prior to fermentation is still 
significantly more potent than the ingredients and by-products which may be attributed to 
the presence of certain phenolic compounds previously observed in beer and wine that have 
been implicated with protective effects against CVD (Arranz et al. 2012).  
 The TPL of the beer was fractionated by TLC and the antithrombotic activity of 
isolated bands was investigated against PAF-induced platelet aggregation, with the results 
displayed in Figure 3.1 and Table 3.3 as previously mentioned. This method of separation 
was a preparatory method used for the isolation and extraction of bioactive lipids which, for 
this study, was for further analysis in the bioassay and displayed similar potent 
antithrombotic properties to literature (Lordan et al. 2019a). However, the study conducted 
by Lordan et al (2019) identified 6 separate bands during the extraction as opposed to the 7 
bands isolated in this study. This could be explained by the isolation of what was thought to 
have been two separate bands, but the results obtained for bands 4 and 5 displayed in Figure 
3.1 and Table 3.3 suggests both were in fact PC. The exploration of the polar lipids observed 
in beer should be further investigated with structural analysis, such as ultra-high 
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performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), to 
provide more insight into the structure-function relationship of these fractions. 
 
4.4 Thin-Layer Chromatography (TLC) 
TLC allowed for the fractionation of the TPL of beer. The bands that were identified 
in the egg yolk according to their Rf values as SM, L-PC, PC, PE and CL which is in 
agreement with the literature (Ternes and Jaekel 2009). 
 Band 1 did not correspond to any of the Rf values of the egg standard and was 
therefore classified as an unknown, however this fraction displayed the highest IC50, 
corresponding to the lowest antithrombic activity than all other phospholipid fraction tested. 
The activity displayed by this fraction did not warrant further analysis.  
 The Rf values of bands 2 and 3 corresponded to L-PC and SM on the egg standard. 
These bands displayed very low IC50’s displaying the strongest antithrombotic activity 
against PAF. However, analysis of L-PC and SM in the past has demonstrated that these 
lipids do not display potent anti-PAF activity to the level of PE which, as seen in Table 3.3, 
was not the case (Antonopoulou and Karantonis 2002; Tsorotioti et al. 2014). This suggests 
that the fractions isolated may not be that of SM and L-PC and could suggest the presence 
of other lipids or phenolic compounds that have been shown to be present in beer and have 
inhibitory action towards PAF (Vlachogianni et al. 2015b). Structural analysis is required to 
identify the compounds present at each fraction as the biological activity displayed by these 
compounds against PAF-induced platelet aggregation warrants further analysis. 
During the extraction of the lipid fractions, bands 4 and 5 were extracted separately as 
it was thought that these could be different fractions, though their similar Rf values and 
levels of antithrombotic activity demonstrated that these bands 4 and 5 were both part of the 
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same fraction with Rf values corresponding to PC. These fractions displayed the same 
biological activity and was statistically significantly higher than the other bands (2,3, and 6) 
which is in accordance with the literature (Nasopoulou et al. 2013a). 
The Rf value of Band 6 corresponded to the Rf value of PE in the egg standard. PE has 
been previously shown to demonstrate strong biological activity against PAF and this is 
reflected in the results obtained in Table 3.3 and Figure 3.1 (Tsorotioti et al. 2014). 
The Rf of band 7 corresponds to CL of the egg standard. This band displayed very 
weak activity against PAF induced platelet-aggregation. Despite displaying a similar Rf 
value to CL, the inhibitory activity of this band was not in accordance with previous studies, 
which found that CL is generally a potent antithrombotic fraction against PAF-induced 
platelet aggregation (Tsoupras et al. 2018a). The activity displayed by this band suggests 
that the phospholipids found here are not that of CL, structural analysis of this band is 
required to definitively identify this band though the activity displayed does not necessarily 
warrant further investigation.   
TLC is an effective technique to facilitate the fractionation and extraction of polar 
lipids though it does have certain limitations. Corresponding Rf values of the sample and the 
standard can indicate the presence of a particular phospholipid, although as can be seen by 
bands 2 and 3, this is not always the case. Further analysis, such as HPLC, is required to 
sufficiently identify these compounds.  
Despite these limitations, TLC allowed for the fractionation, extraction, and 
examination in a bioassay of individual phospholipid classes and clearly demonstrates the 
potent antithrombotic properties of these lipids in the beer against PAF, which accounts for 





The fatty acid profile for the TPL of brewing ingredients and by-products, wort, and 
beer were assessed using GC-MS analysis, the fatty acid composition along with some of 
the phytochemicals detected are displayed in Table 3.4. FAME analysis of these polar lipids 
revealed a higher percentage of 16:0 18:0, 18:1, 18:2, and 18:3 throughout all samples, 
which is similar to the distribution of lipids in the TL of barley, wort and, beer which 
corresponds to the extraction results in Table 3.1, demonstrating that the TPL account for 
74.5% of the TL composition (Evans et al. 2013). This could further support the possibility 
that it is these fatty acids, found in both the TPL and the TL in abundance, that could have 
contributed to the biological activity seen in the TL of some samples.  Little is known about 
the fatty acid composition of the TPL of hops, although the results displayed in Table 3.4 
demonstrate a statistically significant increase in the percentage of these fatty acids from 
RWHP to SPHP with the exception of 18:3, which showed a statistically significant decrease 
in the RWHP to SPHP and wort to beer. The percentage of 20:4 observed in the beer (5.1%) 
is similar to that found in TPL of ale in literature (Lordan et al. 2019a). Furthermore, Table 
3.4 shows that this was a statistically significant increase in percentage of 20:4 when the 
wort (0.5%) was fermented to beer (4.9%). This observation could further support the 
viewpoint that yeast during fermentation can stimulate changes in composition through their 
metabolism. This same observation was made in a study by Lordan  et al (2019) where the 
fermentation of ovine milk to yogurt showed the presence of 20:4 in the TPL of yogurts 
inoculated with different combinations of starter cultures, despite 20:4 not being detected in 
the ovine milk itself, accompanied with a statistically significant improvement of the 
antithrombotic activities the yogurts in comparison to the ovine milk (Lordan et al. 2019c). 
Though not all were statistically significant, an increase in the percentage of 16:0 
accompanied with a reduction in the percentage 18:0, 18:1, and 18:3 was seen between the 
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wort and beer and also in the ovine milk and most yogurt samples of the study by Lordan et 
al, again highlighting the changes fermentation can have to the composition and biological 
function of fatty acids (Lordan et al. 2019c). Some similarities can also be drawn when 
viewing the fatty acid composition of the wort and beer when compared to the classic PAF 
structure. The typical PAF structure is described as composing of 16:0 (68%), 18:0 (27%) 
or 18:1 (4%) in the sn-1 position, an acetic acid on the sn-2 position, and a phosphocholine 
group on the sn-3 position (Demopoulou et al 1979; Lordan et al 2019c). The fatty acid 
content of the beer showed the presence of 16:0 in abundance in the wort (31.8%) and beer 
(32.34%). The analyses detected the presence of 18:0 (c9) in the wort (3.61%) and beer 
(3.32%). The third fatty acid, 18:1, was also detected in the wort (6.1%) and beer (5.62%). 
While the fatty acid composition of the most potent antithrombotic TPL samples shows 
certain similarities to the fatty acid composition of PAF structure, as outlined above, further 
research is required to determine if these structural similarities have a bearing on the 
antithrombotic capabilities of the lipid sample. 
The presence of some phytochemicals was also detected, as can be seen in Table 3.4, 
within the RWHP and SPHP samples which is to be expected as hops are a source of α and 
β-acids for bitterness, essential oils for aroma, and biologically active polyphenols though 
due to their volatile nature many are lost during boiling (van Opstaele et al. 2010; Karabín 
et al. 2016). β-Caryophyllene was found in the highest abundance in the RWHP and SPHP, 
as per Table 3.4, which is in accordance with literature as this sesquiterpene can be found in 
abundance in a variety of hop plants (Kaškonas et al. 2016).  β-caryophyllene has been 
identified as having anticancer properties by affecting the growth and proliferation of cancer 
cells, as well as having analgesic and anti-inflammatory properties (Fidyt et al. 2016) 
highlights the potent bioactivity of this compound. Another biologically active 
phytochemical identified was 2,4-tert-butylphenol though it is not identified in any other 
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samples suggesting it could have been a product of fermentation by the yeast as there is no 
known use of this compound as an additive. This is a possible explanation for the presence 
of this phytochemical in the beer as there is evidence that 2,4-di-tert-butylphenol can be 
synthesised by certain varieties of plants but can also be synthesised by Saccharomyces 
cerevisiae (Shinohara et al 2000). It is not yet known if this photochemical improved the 
antithrombotic activity of the beer TPL as it was present in such a low quantity, but evidence 
has shown that 2,4-di-tert-butylphenol has been observed as an antioxidant, antifungal and 
anti-tumour properties (Varsha et al. 2015). Tau-muurolol, a cadinene sesquiterpene that 
originated in the hops, was the only other naturally present phytochemical found in the beer 












The data obtained in this study demonstrate the potent antithrombotic nature of polar 
lipids within the TPL of beer and related ingredients and by-products. The analysis of the 
fatty acid profile of each sample, compared with the ability of these lipids to inhibit PAF-
induced platelet aggregation, gave an insight into the changes these lipids undergo during 
the brewing process and how these steps effect their biological activity. The changes that 
occur as a direct result of fermentation is one such highlight, with changes being observed 
in the biological activity and fatty acid profile of wort when fermented to beer. This potent 
bioactivity was further investigated with the extraction of isolated lipid fractions by 
preparative TLC which further highlights that the potent bioactivity found in beer could be 
attributed to low amounts of certain classes of phospholipids. This presents a promising 
avenue of research, whereby the wort and beer TPL fractions could be isolated and their 
bioactivity against PAF-induced platelet aggregation can be recorded. Following this, 
structural analysis should be carried out on these fractions to allow the identification of these 
potent PAF-inhibitors and asses how the process of fermentation alters these lipids, making 
them more suited to inhibit the activity of PAF. 
The determination of the fatty acid profile of the TPL of each sample allowed for the 
observation of the changing composition of samples as they went through the brewing 
process, while the TLC analyses showed that different phospholipid classes are responsible 
for different levels of activity against PAF-induced platelet aggregation. This analysis also 
demonstrated the presence of phytochemicals that could potentially contribute to the 
antithrombotic properties observed against PAF-induced platelet aggregation though further 
analysis of these phytochemicals is required. As PAF is directly implicated in chronic 
inflammation, a precursor for many chronic diseases, detailed investigations carried out on 
the structure and functions of these particularly bioactive lipids could lead to the 
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development of certain nutraceuticals that slow or inhibit the action of PAF, lowering the 
levels of inflammation. The BSG forms another potential target for valorisation for 
nutraceuticals or for the development of functional foods as the bioactivities demonstrated 
by the TL of the BSG warrant further investigation. The level of inhibition of the TL of the 
BSG against PAF-induced platelet aggregation, coupled with the vast quantity of this by-
product produced annually, makes this by-product of the brewing industry a potential target 
for improved cardiovascular health. 
This study contributes to the data surrounding the effects of fermentation on the 
improved biological activity of lipids, presents BSG as a potential target to be utilised in 
combatting the development of CVD and provides new information into the fatty acid 





Figure 8. Image displaying the calibration curve used in the GC-MS analyses to calculate 





Figure 9. Photograph taken of the TLC plate used for the fractionation of the beer polar 
lipids.  
This image was taken after removal from the visualization tank. The centre column contains 
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